

Patient Safety Technologies, Inc
Form 10-Q
November 19, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 001-09727

PATIENT SAFETY TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

13-3419202
(I.R.S. Employer Identification No.)

Two Venture Plaza, Suite 350, Irvine, CA 92618
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (949) 387-2277

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if smaller reporting company) Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The number of outstanding shares of the registrant's common stock, par value \$0.33 per share, as of November 15, 2010 was 23,456,063.

PATIENT SAFETY TECHNOLOGIES, INC.

FORM 10-Q FOR THE QUARTER
ENDED SEPTEMBER 30, 2010

TABLE OF CONTENTS

	Page
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	i
HELPFUL INFORMATION	i
PART I – FINANCIAL INFORMATION	1
ITEM 1. FINANCIAL STATEMENTS	1
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations	2
Condensed Consolidated Statements of Cash Flows	3
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	31
ITEM 4. CONTROLS AND PROCEDURES	31
PART II – OTHER INFORMATION	32
ITEM 1. LEGAL PROCEEDINGS	32
ITEM 1A. RISK FACTORS	32
ITEM 1A. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	32
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	32
ITEM 4. (REMOVED AND RESERVED)	32
ITEM 5. OTHER INFORMATION	32
ITEM 6. EXHIBITS	33
SIGNATURES	34

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can sometimes identify forward-looking statements by our use of forward-looking words like “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “seeks,” “predicts,” “potential,” or “continue” or of these terms and other similar expressions. Our forward-looking statements relate to future events or our future performance and include, but are not limited to, plans, objectives, expectations and intentions. Other statements contained in this report that are not historical facts are also forward-looking statements.

Although we believe that the plans, objectives, expectations and intentions reflected in or suggested by our forward-looking statements are reasonable, those statements are based only on the current beliefs and assumptions of our management and on information currently available to us and, therefore, they involve uncertainties and risks as to what may happen in the future. Accordingly, we cannot guarantee that our plans, objectives, expectations or intentions will be achieved. Our actual results, performance (financial or operating) or achievements could differ from those expressed in or implied by any forward-looking statement in this report as a result of many known and unknown factors, many of which are beyond our ability to predict or control. These factors include, but are not limited to, those described under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2009 filed on March 31, 2010 and amended on April 30, 2010, including without limitation the following:

- our need for additional financing to support our business;
- the early stage of adoption of our Safety-Sponge® System and the need to expand adoption of our Safety-Sponge® System;
 - any failure of our new management team and Board of Directors to operate effectively;
- our reliance on third-party manufacturers, some of whom are sole-source suppliers, and on our exclusive distributor; and
 - any inability to successfully protect our intellectual property portfolio.

The risks included in our filings are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements.

Our forward-looking statements speak only as of the date they are made and should not be relied upon as representing our plans, objectives, expectations and intentions as of any subsequent date. Although we may elect to update or revise forward-looking statements at some time in the future, we specifically disclaim any obligation to do so, even if our plans, objectives, expectations or intentions change.

HELPFUL INFORMATION

As used throughout this quarterly report on Form 10-Q, the terms the “Company,” “the registrant,” “we,” “us,” and “our” mean Patient Safety Technologies, Inc., a Delaware corporation, together with its consolidated subsidiary, SurgiCount

Edgar Filing: Patient Safety Technologies, Inc - Form 10-Q

Medical Inc., a California corporation, unless the context otherwise requires.

Unless otherwise indicated, all statements presented in this quarterly report on Form 10-Q regarding cumulative number of surgical sponges used and numbers of procedures are internal estimates only.

Safety-Sponge®, SurgiCounter™ and Citadel™, among others, are registered or unregistered trademarks of Patient Safety Technologies, Inc. (including its subsidiary).

i

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PATIENT SAFETY TECHNOLOGIES, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(Unaudited)

	September 30, 2010	December 31, 2009
Assets		
Current assets:		
Cash and cash equivalents	\$ 2,796,742	\$ 3,446,726
Restricted cash	223,630	—
Accounts receivable, net	679,760	906,136
Inventories, net	1,729,969	565,823
Prepaid expenses	256,057	207,598
Total current assets	5,686,158	5,126,283
Property and equipment, net	918,563	744,646
Goodwill	1,832,027	1,832,027
Patents, net	2,870,318	3,114,025
Long-term investment	666,667	666,667
Other assets	48,801	43,246
Total assets	\$ 12,022,534	\$ 11,526,894
Liabilities and Stockholders' Equity (Deficit)		
Current liabilities		
Accounts payable	\$ 1,677,252	\$ 2,043,166
Accrued liabilities	865,608	1,242,876
Convertible note payable	1,424,558	1,424,558
Capital lease-current portion	—	19,330
Warrant derivative liability	980,757	3,666,336
Deferred revenue	4,446,647	8,099,144
Total current liabilities	9,394,822	16,495,410
Capital lease, less current portion	—	58,274
Deferred tax liability	708,049	805,768
Total liabilities	10,102,871	17,359,452
Commitments and contingencies (Note 20)		
Stockholders' equity(deficit):		
Series A preferred stock, \$1.00 par value, cumulative 7% dividend: 1,000,000 shares authorized; 10,950 issued and outstanding at September 30, 2010 and December 31, 2009; (Liquidation preference of \$1.2 million at September 30, 2010 and December 31, 2009)		
	10,950	10,950
Series B convertible preferred stock, \$1.00 par value, cumulative 7% dividend: 150,000 shares authorized; 60,067 issued and outstanding at September 30, 2010		

Edgar Filing: Patient Safety Technologies, Inc - Form 10-Q

and 0 issued and outstanding at December 31, 2009;

(Liquidation preference of \$6.0 million at September 30, 2010 and \$0 at December 31, 2009)

	60,067	—
Common stock, \$0.33 par value: 100,000,000 shares authorized; 23,456,063 shares issued and outstanding at September 30, 2010 and December 31, 2009	7,740,501	7,740,501
Additional paid-in capital	51,266,092	44,834,321
Accumulated deficit	(57,157,947)	(58,418,330)
Total stockholders' equity (deficit)	1,919,663	(5,832,558)
Total liabilities and stockholders' equity (deficit)	\$ 12,022,534	\$ 11,526,894

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

PATIENT SAFETY TECHNOLOGIES, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Revenues	\$ 4,122,560	\$ 978,461	\$ 10,252,897	\$ 2,942,066
Cost of revenue	1,950,573	540,013	4,829,821	1,707,575
Gross profit	2,171,987	438,448	5,423,076	1,234,491
Operating expenses:				
Research and development	35,246	69,270	166,548	267,851
Sales and marketing	518,570	609,921	2,341,132	1,812,146
General and administrative	693,235	1,256,580	4,849,573	5,162,428
Total operating expenses	1,247,051	1,935,771	7,357,253	7,242,425
Operating income (loss)	924,936	(1,497,323)	(1,934,177)	(6,007,934)
Other income (expense)				
Interest income (expense)	3,598	(303,580)	(5,062)	(744,000)
Gain (loss) on change in fair value of warrant derivative liability	15,631	(1,762,384)	2,685,579	(4,332,503)
Other income (expense)	—	194,447	433,958	194,447
Total other income (expense)	19,229	(1,871,517)	3,114,475	(4,882,056)
Income (loss) before income taxes	944,165	(3,368,840)	1,180,298	(10,889,990)
Income tax benefit	32,573	31,758	139,862	96,477
Net income (loss)	976,738	(3,337,082)	1,320,160	(10,793,513)
Preferred dividends	(14,682)	(19,163)	(59,777)	(57,488)
Net income (loss) applicable to common shareholders	\$ 962,056	\$ (3,356,245)	\$ 1,260,383	\$ (10,851,001)
Income (loss) per common share				
Basic	\$ 0.04	\$ (0.17)	\$ 0.05	\$ (0.60)
Diluted	\$ 0.04	\$ (0.17)	\$ 0.04	\$ (0.60)
Weighted average common shares outstanding:				
Basic	23,456,063	20,229,483	23,456,063	18,219,514
Diluted	24,031,063	20,229,483	35,659,766	18,219,514

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

PATIENT SAFETY TECHNOLOGIES, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Nine Months Ended September 30,	
	2010	2009
Operating activities:		
Net income (loss)	\$ 1,320,160	\$ (10,793,513)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation	388,006	253,496
Amortization of patents	243,706	243,706
Amortization of debt discount	—	461,000
Stock based compensation	965,078	896,326
Gain on reduction of contingent tax liability	(427,700)	
Warrant exchange	—	(193,000)
Loss on abandonment of lease	151,973	—
Loss on capital lease write-off	3,917	—
Non-cash interest	—	1,323,000
(Gain) loss on change in fair value of warrant derivative liability	(2,685,579)	4,333,136
Change in deferred tax liability	(97,719)	(97,079)
Changes in operating assets and liabilities:		
Accounts receivable	226,376	232,200
Inventories	(1,164,147)	(530,000)
Prepaid expenses	(48,459)	(10,333)
Other assets	(5,554)	8,000
Accounts payable	634,086	897,022
Accrued liabilities	(101,540)	(100,649)
Deferred revenue	(3,652,497)	—
Net cash used in operating activities	(4,249,893)	(3,076,688)
Investing activities:		
Purchase of property and equipment	(627,888)	(89,020)
Net cash used in investing activities	(627,888)	(89,020)
Financing activities:		
Proceeds from issuance of notes payable	—	2,000,000
Proceeds from issuance of convertible preferred stock and warrants	—	1,706,000
Proceeds from issuance of convertible preferred stock	5,000,000	—
Payments for stock issuance costs	(480,010)	
Capital lease principle payments	(15,556)	—
Payments of preferred dividends	(53,007)	(57,488)
Transfer to restricted cash in connection with tax escrow account	(223,630)	—
Net cash provided by financing activities	4,227,797	3,648,512
Net increase (decrease) in cash and cash equivalents	(649,984)	482,804
Cash and cash equivalents at beginning of period	3,446,726	296,185
Cash and cash equivalents at end of period	\$ 2,796,742	\$ 778,989

Edgar Filing: Patient Safety Technologies, Inc - Form 10-Q

Supplemental disclosures of cash flow information:

Cash paid during the period for interest	\$	—	\$	36,000
Cash paid during the period for taxes	\$	16,113	\$	—
Non cash investing and financing activities:				
Issuance of convertible preferred stock for accounts payable	\$	1,000,000	\$	—
Dividends accrued	\$	53,007	\$	57,488
Reduction of fixed assets based on write-off of capital lease	\$	62,048	\$	—
Payment of Series B preferred dividends in shares	\$	6,770	\$	—
Reclassification of accrued interest to notes payable	\$	—	\$	165,000
Debt discount recorded in connection with issuance of notes payable	\$	—	\$	1,311,311
Reclassification of warrant equities to derivative liability	\$	—	\$	4,240,000
Issuance of common stock in payment of notes payable and accrued interest	\$	—	\$	(258,000)
Cancellation of warrants in connection with warrant exchange	\$	—	\$	(5,722,036)
Reclassification of warrant derivative liability to equity	\$	—	\$	(2,152,940)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1. DESCRIPTION OF BUSINESS

Patient Safety Technologies, Inc. is a Delaware corporation, conducts its operations through its wholly-owned operating subsidiary, SurgiCount Medical, Inc. ("SurgiCount"), a California corporation. References to the "Company" include references Patient Safety Technologies, Inc. and SurgiCount, unless the context otherwise requires.

The Company's operating focus is the development, marketing and sales of products and services focused in the medical patient safety markets. The SurgiCount Safety-Sponge® System is a patented system of bar-coded surgical sponges, SurgiCounter™ scanners, and software applications integrated to form a comprehensive counting and documentation system. This system is designed to reduce the number of retained surgical sponges unintentionally left inside of patients during surgical procedures by allowing faster and more accurate counting of surgical sponges.

2. LIQUIDITY AND GOING CONCERN

The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern. At September 30, 2010, the Company had a working capital deficit of \$3.7 million, and for the nine-month period ended September 30, 2010, the Company incurred an operating loss of \$1.9 million and generated negative cash flow from operating activities of \$4.3 million.

In the most recent audit report dated March 31, 2010 by the Company's independent registered public accounting firm, Squar Milner, included an explanatory paragraph in which they stated that the significant recurring net losses through December 31, 2009 and the significant working capital deficit at December 31, 2009 raised substantial doubt about the Company's ability to continue as a going concern.

In June 2010, the Company augmented its cash resources by completing a convertible preferred stock financing transaction that generated gross proceeds of \$5.0 million. Starting in the most recent quarter ended September 30, 2010, newly appointed management implemented a comprehensive restructuring effort focused on a number of initiatives, including reducing operating expenses and achieving positive operating income and operating cash flow. During the most recent quarter ended September 30, 2010, the Company reported revenue of \$4.1 million and operating income of \$925 thousand, which is the first time that the Company has reported positive operating income since the Company's acquisition of SurgiCount Medical in 2005. Although cash flow from operating activities during the quarter ended September 30, 2010 were negative \$2.1 million, this result included a payment of \$2.4 million for past due amounts owed to the primary manufacturing vendor of our sponge products, A Plus International, Inc. (A Plus"). Our cash flow from operating activities for the quarter ended September 30, 2010 when adjusted to remove this payment to A Plus, would have resulted in the quarterly operating cash flow from operating activities being positive or adding to the cash balance on hand. Operating income of \$925 thousand during the quarter ended September 30, 2010 included \$1.3 million of gross profit attributable to sales to Cardinal Health, our exclusive distributor, under our agreement with them that includes provisions for their purchase of stocking orders throughout 2010. However, management still considers this quarter's positive operating profit result to be a meaningful milestone event, given the Company's history of reporting operating losses. The improvements in both cash flow and income from operations during the third quarter of 2010 as compared to previous periods was the result of a number of items, including the restructuring initiative recently implemented by newly appointed management and continued growth in the Company's revenue, which included revenue attributable stocking orders from Cardinal Health. The Company's revenue and gross profit during the first nine months of 2010 of \$10.3 million and \$5.4 million respectively, have grown 248% and 340% respectively, compared to the first nine months of 2009.

Despite the improvements in operating performance achieved in the three and nine months ended September 30, 2010, management believes that it will be necessary to raise additional funds before the end of the first quarter 2011 in order to continue to operate as a going concern. Management believes that if necessary, additional cost-cutting measures can be implemented to extend the Company's ability to operate its core business beyond the first quarter 2011 if

financing is not timely available. Management's plan to raise additional required funding could include equity and or debt financings, in private transactions with accredited investors. The Company has historically been successful in raising required financing in this manner, and believes that it will be able to raise such additional financing on a timely basis. However, no assurances can be made that the Company will be successful in obtaining a sufficient amount of financing on acceptable terms (or any financing) in order to continue to fund its operations, or that it will be able to continue to achieve profitable operating results or positive cash flow. In addition, no assurance can be made that additional cost cutting measures, if implemented, will materially extend the Company's ability to operate without procuring additional financing. The accompanying condensed consolidated interim financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and applicable sections of Regulation S-X and do not include all the information and disclosures required by accounting principles generally accepted in the United States of America. The condensed consolidated interim financial information is unaudited but reflects all normal adjustments and disclosures that are, in the opinion of management, necessary to make the financial statements not misleading. The condensed consolidated balance sheet as of December 31, 2009 was derived from the Company's audited financial statements. The condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2009. Results of the three and nine months ended September 30, 2010 are not necessarily indicative of the results to be expected for the full year ending December 31, 2010.

Principles of Consolidation

The accompanying condensed consolidated interim financial statements for 2010 include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions include, but are not limited to, assessing the following: the valuation of accounts receivable and inventory, impairment of goodwill and other intangible assets, the fair value of stock-based compensation and derivative liabilities, valuation allowance related to deferred tax assets, warranty obligations, provisions for returns and allowances and the determination of assurance of the collection of revenue arrangements.

Reclassifications

Certain prior year amounts have been reclassified to conform to the 2010 presentation. These reclassifications had no effect on previously reported results of operations or accumulated deficit.

Revenue Recognition

The Company recognizes revenue from the sale of products to end-users and distributors when persuasive evidence of a sale exists, the product is complete, tested and has been shipped which coincides with transfer of title and risk of loss, the sales price is fixed and determinable, collection of the resulting receivable is reasonably assured, there are no material contingencies and the Company does not have significant obligations for future performance. When collectability is not reasonably assured, the Company defers the revenue until cash payment is received. Provisions for estimated future product returns and allowances are recorded in the period of the sale based on the historical and anticipated future rate of returns. The Company records shipping and handling costs charged to customers as revenue and shipping and handling costs to cost of revenue as incurred. Revenue is recorded net of any discounts or trade-in allowances given to the buyer.

- **Hardware Cost Reimbursement Revenues:** Beginning with the third quarter of 2009, the Company modified its business model and began to offer its SurgiCounter™ scanners and related hardware and software to all hospitals at no cost when they adopt its Safety-Sponge® System. Prior to the third quarter of 2009, the Company's business model included the sale of its SurgiCounter™ scanners and related hardware and software used in its Safety-Sponge® System to most hospitals that adopted the Company's system. Under the supply and distribution agreement with Cardinal Health entered into in November 2009, the Company is reimbursed an agreed upon percentage of the cost of the scanners provided by the Company to hospitals that receive their surgical sponges and towels through Cardinal Health. Reimbursements received from Cardinal Health are initially deferred and are recognized as revenue on a pro-rata basis over the life of the specific hospital contract. Because the Company no longer engages primarily in direct SurgiCounter™ scanner and related hardware sales, except in certain customer specific situations, it generally anticipates only recognizing revenues associated with its SurgiCounter™ scanners in connection with reimbursement arrangements under its agreement with Cardinal Health.
- **Hardware, Software and Maintenance Agreement Revenues:** Because the software included in the Company's SurgiCounter™ scanner is not incidental to the product being sold, the sale of the software falls within the scope of Accounting Standards Codification ("ASC") ASC 985-605, formerly Statement of Position ("SOP") 97-2. The SurgiCounter™ scanner is considered to be a software-related element, as defined in ASC 985-605, because the software is essential to the functionality of the scanner, and the maintenance agreement, which provides for product support including unspecified product upgrades and enhancements developed by the Company during the period covered by the agreement, is considered to be post-contract customer support ("PCS") as defined in ASC 985-605. Prior to the third quarter of 2009, our business model included the sale of our SurgiCounter™ scanners and related software used in our Safety-Sponge® System to most hospitals that adopted our system. Beginning with the third quarter of 2009, we modified our business model and began to provide our SurgiCounter™ scanners and related software to all hospitals at no cost when they adopt our Safety-Sponge® System. Because we no longer engage primarily in direct SurgiCounter™ scanner sales, we generally anticipate only recognizing revenues associated with our SurgiCounter™ scanners in connection with reimbursement arrangements under our agreement with Cardinal Health. Therefore, we do not expect that our SurgiCounter™ scanners and related hardware will represent a sizable source of future revenues for us. Deferred scanner revenue associated with the reimbursement from Cardinal Health, will be recognized over the life of the specific hospital contract.
- **Sales of our sponges and towels are generally considered to be at the time of shipment where terms are FOB shipping point.** In the event that terms of the sale are FOB customer, the delivery is considered to occur at the time that delivery to the customer has been completed. Delivery with respect to the initial one-year maintenance agreement is considered to occur on a monthly basis over the term of the one-year period, and revenues related to this element are recognized on a pro-rata basis during this period. Costs of scanners and related hardware and software are capitalized and depreciated to Cost of Sales with an assumed three year life.
- **Surgical Sponge Revenues:** The surgical products (sponges and towels) used in the Company's Safety-Sponge® System are sold separately from the hardware and software described above, and those products are not considered to be part of a multiple-element arrangement. Accordingly, revenues related to the sale of products used in the Company's Safety-Sponge® System are recognized in accordance with ASC 605-25 that addresses revenue recognition for multiple-element arrangements. Generally revenues from the sale of surgical products used in the Safety-Sponge® System are recognized upon shipment as most surgical products used in the Safety-Sponge® System are sold FOB shipping point. In the event that terms of the sale are FOB customer, revenue is recognized at the time delivery to the customer has been completed. Advanced payments are classified as deferred revenue and recognized as product is shipped to the customer.

Recent Accounting Pronouncements

In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2009-13, Multiple Deliverable Revenue Arrangements, which addresses the accounting for multiple deliverable arrangements to enable vendors to account for products and services (deliverables) separately rather than as a combined unit. The amendments in ASU 2009-13 are effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The impact of this accounting update on the Company’s consolidated financial statements has not been evaluated.

In October 2009, the FASB issued ASU 2009-14, Certain Revenue Arrangements That Include Software Elements, which changes the accounting model for revenue arrangements that include both tangible products and software elements that are “essential to the functionality,” and scopes these products out of current software revenue guidance. The new guidance will include factors to help companies determine what software elements are considered “essential to the functionality.” The amendments included in ASU 2009-14 are effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The impact of this accounting update on the Company’s consolidated financial statements has not been evaluated.

In January 2010, the FASB issued ASU 2010-06, “Fair Value Measurements and Disclosures (Topic 20): Improving Disclosures about Fair Value Measurements.” This ASU provides clarification regarding existing disclosures and requires additional disclosures regarding fair value measurements. Specifically, the guidance now requires reporting entities to disclose the amounts of significant transfers between levels and the reasons for the transfers. In addition, the reconciliation should present separate information about purchases, sales, issuances and settlements. A reporting entity should provide disclosures about the valuation techniques and inputs used to measure fair value. The new standard was effective for reporting periods beginning after December 15, 2009 except for disclosures about purchases, sales, issuances and settlements, which is not effective until reporting periods beginning after December 15, 2010. There were no transfers into or out of Level 1 or Level 2 of the fair value hierarchy during the nine months ended September 30, 2010. Adoption of the not yet effective section of this guidance is not expected to have a material impact on our Consolidated Financial Statements.

4. RESTRICTED CASH

Restricted cash at September 30, 2010 consists of \$224 thousand of cash held in an escrow account pursuant to the Tax Escrow Agreement, which was established during the quarter ended June 30, 2010 in connection with the Convertible Preferred Stock financing transaction (see Note 20). Cash held in the escrow account is invested in the escrow agent’s insured money market account and any income earned on such funds is added to the balance held in escrow. In accordance with the terms of the Tax Escrow Agreement, funds held in the escrow account may be released to pay tax claims by federal or state taxing authorities, or in the event that the Company’s estimated contingent tax liability, as reflected in its periodic reporting on either Form 10-Q or 10-K, is reduced for reasons other than actual payment of tax claims, subject to compliance with specific provisions of the agreement. During the nine months ended September 30, 2010 the initial contingent tax liability of \$651 thousand was reduced by \$427 thousand based on the expiration of the federal statute of limitations relating to certain 2006 income. The Company anticipates the remaining \$224 thousand balance of restricted cash will be released from the escrow account by the second quarter of 2011 based on the expiration of the federal statute of limitations relating to the tax year 2007.

5. EARNINGS (LOSS) PER COMMON SHARE

Earnings (loss) per common share are determined by dividing the earnings (loss) applicable to common shareholders by the weighted average number of common shares outstanding. The Company complies with FASB Accounting Standards Codification (“ASC”) 260-10 Earnings Per Share (previously SFAS No. 128, Earnings per Share), which requires dual presentation of basic and diluted earnings (loss) per share on the face of the condensed consolidated statements of operations. Basic loss per common share excludes dilution and is computed by dividing loss attributable to common stockholders by the weighted-average common shares outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if convertible preferred stock or notes, options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity.

For the three and nine months ended September 30, 2010, the shares associated with the convertible note (see Note 10), convertible preferred stock and warrants and options that have a conversion/exercise price in excess of the average stock price during the three and nine month periods ending September 30, 2010, respectively, are included in

calculating diluted earnings per share. Because the effects of outstanding options, warrants, convertible note and convertible preferred stock that have conversion/exercise prices in excess of the average stock price during the three and nine month periods ended September 30, 2010, are anti-dilutive, shares of common stock underlying these instruments as shown below have been excluded from the computation of loss per common share for the three and nine months ended September 30, 2009, respectively.

7

Edgar Filing: Patient Safety Technologies, Inc - Form 10-Q

The following table sets forth the computation of basic and diluted earnings (loss) per share:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2010	2009	2010	2009
Basic				
Income (loss) available to common stockholders	\$ 962,056	\$ (3,356,245)	\$ 1,260,383	\$ (10,851,001)
Weighted average common shares outstanding (basic)	23,456,063	20,229,483	23,456,063	18,219,514
Basic income (loss) per common share	\$ 0.04	\$ (0.17)	\$ 0.05	\$ (0.60)
Diluted				
Income (loss) available to common stockholders	\$ 962,056	\$ (3,356,245)	\$ 1,260,383	\$ (10,851,001)
Weighted average common shares outstanding	24,031,063	20,229,483	23,456,063	18,219,514
Assumed issuance of restricted stock	75,000	—	75,000	—
Assumed exercise of options	—	—	1,052,084	—
Assumed conversion of Series B preferred stock	—	—	8,008,933	—
Assumed exercise of warrants	—	—	2,567,686	—
Assumed conversion of debt	500,000	—	500,000	—
Common and potential common shares	24,031,063	20,229,483	35,659,766	18,219,514
Diluted income (loss) per common share	\$ 0.04	\$ (0.17)	\$ 0.04	\$ (0.60)
Potentially dilutive securities outstanding at period end excluded from diluted computation as they were anti-dilutive	16,250,850	12,003,201	8,896,863	12,003,201

6. INVENTORY, NET

Inventory consists of the following:

	September 30,	December 31,
	2010	2009
Finished goods	\$ 1,898,965	\$ 734,819
Reserve for obsolescence	(168,996)	(168,996)
Total inventory, net	\$ 1,729,969	\$ 565,823

7. PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

	September 30, 2010	December 31, 2009
Computer software and equipment	\$ 1,100,003	\$ 1,097,181
Furniture and equipment	226,586	298,333
Hardware for customer use	1,025,709	394,861
Property and equipment, gross	2,357,298	1,790,375
Less: accumulated depreciation	(1,433,735)	(1,045,729)
Property and equipment, net	\$ 918,563	\$ 744,646

At June 30, 2010, based on the Company's decision to close the Newtown, PA office, the Company wrote off the remaining capital lease of \$66 thousand pertaining to office furniture acquired as part of the Newtown, PA sublease.

8. GOODWILL AND PATENTS

The Company recorded goodwill in the amount of \$1.7 million in connection with its acquisition of SurgiCount in February 2005. During the year ended December 31, 2007, cumulative gross revenues of SurgiCount exceeded \$1.0 million and as such the Company issued 100,000 shares of common stock, valued at approximately \$145 thousand to the SurgiCount founders, as contingent consideration, which was recorded as additional goodwill. In addition, in connection with the SurgiCount acquisition, the Company recorded patents acquired that were valued at \$4.7 million.

Patents, net, consists of the following:

	September 30, 2010	December 31, 2009
Patents	\$ 4,684,576	\$ 4,684,576
Accumulated amortization	(1,814,258)	(1,570,551)
Patents, net	\$ 2,870,318	\$ 3,114,025

The patents are subject to amortization over their estimated useful life of 14.4 years. Amortization expense for the three and nine months ended September 30, 2010 and 2009 was \$81 thousand and \$244 thousand, respectively.

9. LONG-TERM INVESTMENTS

Long-term investments consists of the following:

	September 30, 2010	December 31, 2009
Alacra, Inc.	\$ 666,667	\$ 666,667
Total	\$ 666,667	\$ 666,667

At September 30, 2010 and December 31, 2009, the Company had an investment in shares of Series F convertible preferred stock of Alacra, Inc. ("Alacra"), a global provider of business and financial information in New York, recorded at its cost of \$667 thousand. In December 2007, we received proceeds of \$333 thousand from the redemption of one-third of our initial \$1.0 million investment. In accordance with the terms of our investment, we have exercised our right to redeem our remaining preferred stock to Alacra, however to date the Company has not complied with our redemption rights. We intend to exercise all of our rights and expect to receive the full carrying

value due to us from this investment. As there is no readily determinable fair value of the Alacra preferred stock, we account for this investment under the cost method.

9

10. CONVERTIBLE NOTE PAYABLE

Effective June 1, 2007, the Company restructured the entire unpaid principal and interest under promissory notes issued to Ault Glazer Capital Partners, LLC (“Ault Glazer”), into a new Convertible Secured Promissory Note (the “AG Capital Partners Convertible Note”) in the principal amount of \$2.5 million. The AG Capital Partners Convertible Note bears interest at the rate of 7% per annum and is due on the earlier of December 31, 2010, or the occurrence of an event of default.

On September 5, 2008, the Company entered into an Amendment and Early Conversion of the Secured Convertible Promissory Note (the “Amendment”) to modify the terms of the AG Capital Partners Convertible Note. Under the Amendment, the Company agreed to pay Ault Glazer \$450 thousand in cash and, contingent upon satisfaction of certain conditions by Ault Glazer, convert the remaining balance of the convertible secured note into 1,300,000 shares of the Company’s common stock. One condition was that Ault Glazer transfers certain leases from the Company’s name into its name. The Company made the \$450 thousand cash payment on September 5, 2008.

On September 12, 2008, the parties executed an Agreement for the Advancement of Common Stock Prior to Close of the Amendment and Early Conversion of Secured Convertible Promissory Note, dated September 5, 2008 (the “Advancement”). Pursuant to the Advancement, the Company agreed to issue 300,000 shares of the Company’s common stock to Ault Glazer on September 12, 2008, in advance of the satisfaction of the conditions for conversion in the Amendment, with the understanding that Ault Glazer would satisfy the conditions stated in the Amendment prior to September 19, 2008.

Ault Glazer failed to satisfy the conditions by the September 19, 2008 deadline. Although the conditions remained unsatisfied, the Company made two additional issuances of shares to Ault Glazer pursuant to the Amendment as follows: the Company issued another 250,000 shares on October 10, 2008 and another 250,000 shares on November 6, 2008. As of September 30, 2010 and December 31, 2009, there remain 500,000 shares issuable to Ault Glazer upon Ault Glazer meeting the conditions of the Amendment. During the three and nine months ended September 30, 2010 and the year ended December 31, 2009, in light of the failure to satisfy the conditions of the Amendment and the Advancement, the Company did not accrue interest expense on the AG Capital Partners Convertible Note.

In October 2010, the Company received a Notice of Levy (the “Levy”) from the US Marshal’s Office in Los Angeles (“Levying Officer”) with an order requiring the Company to deliver all shares of Patient Safety Technologies common stock (“PST Stock”) that the Company owes to Ault Glazer Capital Partners, LLC to the Levying Officer on behalf of a creditor who holds a judgment against Ault Glazer Partners, LLC and other parties. The Company is currently reviewing the Levy and intends to comply with its legal obligations in regard to the Levy (see Note 21).

11. ACCRUED LIABILITIES

Accrued liabilities consists of the following:

	September 30, 2010	December 31, 2009
Accrued lease liability	\$ 98,826	\$ 7,547
Accrued dividends on preferred stock	114,976	114,976
Accrued severance	301,371	47,449
Accrued director’s fees	—	162,500
Contingent tax liability	223,523	740,726
Accrued commissions	—	13,200
Other	126,912	156,478
Total accrued liabilities	\$ 865,608	\$ 1,242,876

12. DEFERRED REVENUE

Deferred revenue consists of the following:

	September 30, 2010	December 31, 2009
Cardinal Health advance payment on purchase order	\$ 4,131,148	\$ 8,000,000
Scanner reimbursement revenue	311,749	99,144
Maintenance agreements	3,750	—
Total	\$ 4,446,647	\$ 8,099,144

On November 19, 2009 we entered into a Supply and Distribution Agreement with Cardinal Health (which replaced our prior agreement with Cardinal Health) under which Cardinal Health is the exclusive distributor of current products used in our proprietary Safety-Sponge® System in the United States, Puerto Rico and Canada. In connection with the execution of this distribution agreement, Cardinal Health issued a \$10.0 million stocking purchase order ("First Forward Order"), paid us \$8.0 million in cash as a partial prepayment of the First Forward Order and agreed to pay \$2.0 million directly to A Plus International, Inc. ("A Plus"), our exclusive manufacturer, upon delivery of product to Cardinal Health. We did not ship any product pursuant to the First Forward Order in 2009, and accordingly, all \$10.0 million of revenue from the First Forward Order is expected to be recognized in 2010. As of September 30, 2010, we had recognized \$5.9 million in revenue from the First Forward Order, and Cardinal Health has made payments totaling \$2.0 million to A Plus. In addition, Cardinal Health had originally agreed to issue a \$5.0 million stocking purchase order ("Second Forward Order") before the end of the third quarter of 2010 if certain milestones were achieved, however both the Company and Cardinal Health have agreed not to pursue this Second Forward Order. We expect to have revenue of \$10.0 million in 2010 from the First Forward Order, and \$0 revenue from the First and Second Forward Orders in 2011.

Because of this arrangement, we expect that our revenues for 2010 will be significantly higher than the actual sales of our product by Cardinal Health to end-user hospital customers. However, the Company's revenue in 2011 and beyond could be materially lower than actual sales of our product made by Cardinal Health to end-user hospital customers. Under the terms of the Supply and Distribution Agreement with Cardinal Health, beginning in 2011 Cardinal Health may adjust its inventory to more normal levels gradually over a 12 month period. Should Cardinal Health reduce its orders to the Company in an effort to gradually reduce its inventory levels to more normal levels over a 12-month period, Company revenues could be materially negatively affected. The Company is in discussions with Cardinal Health to delay the inventory reduction in 2011 and discuss a mutually acceptable process for Cardinal Health to use their Forward Order inventory in satisfying customer demand, so as to avoid having a significant negative impact, if any, on the Company's future revenue in 2011 and beyond as a result of this arrangement, and believes that a mutual agreement will be reached between the Company and Cardinal Health, however no assurances can be made that such an agreement will be reached.

Prior to the third quarter of 2009, the Company's business model included the sale of its SurgiCounter™ scanners and related software used in the Company's Safety-Sponge® System to most hospitals that adopted its system. Beginning with the third quarter of 2009, the Company modified its business model and began to offer to provide its SurgiCounter™ scanners and related hardware and software to hospitals at no cost when they adopt its Safety-Sponge® System. Under the new supply and distribution agreement with Cardinal Health entered into in November 2009, the Company is reimbursed an agreed upon percentage of the cost of the scanners provided by the Company to hospitals that receive their surgical sponges and towels through Cardinal. Reimbursements received from Cardinal are initially deferred and are recognized as revenue on a pro-rata basis over the life of the specific hospital contract. The balance of the deferred revenue to Cardinal related to scanners as of September 30, 2010 was \$311 thousand. Because the

Company no longer engages primarily in direct SurgiCounter™ scanner and related hardware sales, except in certain customer specific situations, it generally anticipates only recognizing revenues associated with its SurgiCounter™ scanners in connection with reimbursement arrangements under its agreement with Cardinal Health.

13. SERIES B CONVERTIBLE PREFERRED STOCK

On June 24, 2010 the Company entered into a Convertible Preferred Stock Purchase Agreement with several accredited investors, as defined under Rule 501(a) of the Securities Act of 1933, as amended. The accredited investors included A Plus International, Inc. and Catalysis Partners, LLC. Wenchen (Wayne) Lin, a member of the Company's Board of Directors, is a founder and significant beneficial owner of A Plus International, Inc and John P. Francis, a member of the Company's Board of Directors, has voting and investment control over securities held by Francis Capital Management, LLC, which acts as the investment manager for Catalysis Partners, LLC. Pursuant to the Convertible Preferred Stock Purchase Agreement, the Company issued an aggregate of 60,000 shares of its Series B Convertible Preferred Stock ("Series B Preferred"), at a purchase price of \$100 per share, or \$6 million in the aggregate, payable in cash or as a reduction of indebtedness or a combination of both. Ten thousand of the Series B preferred shares valued at \$1.0 million were issued and exchanged for \$1.0 million of accounts payable balance that the Company owed A Plus International, the primary manufacturing supplier of the Company's sponge products. The Company authorized 150,000 shares of Series B Preferred, with a par value of \$1.00 per share. Holders of the Series B Preferred are entitled to receive quarterly cumulative dividends at a rate of 7.00% per annum, beginning on July 1, 2010. All dividends due on or prior to December 31, 2011 are payable in kind in the form of additional shares of Series B Preferred, and all dividends payable after December 31, 2011 are payable solely in cash. On November 15, 2010 the Company's Board of Directors declared dividends on the Series B Preferred stock covering the period June 24, 2010 (the date of issuance) through to September 30, 2010, totaling \$110 thousand. The dividend will be paid to the Series B Preferred shareholders during the quarter ended December 31, 2010 by issuing an additional 1,089 shares of Series B Preferred shares, valued at \$100 per share, and cash of \$1,175, reflecting fractional share amounts.

In connection with the Convertible Preferred Stock Purchase Agreement, the Company and the investors entered into a Registration Rights Agreement. Pursuant to the Registration Rights Agreement, the Company is required to use its reasonable best efforts to file with the Securities and Exchange Commission a registration statement covering the shares of common stock underlying the Series B Preferred Stock within 90 days from the closing date of June 24, 2010, and to cause the registration statement to be declared effective within 150 days of the closing date, and to maintain the effectiveness of the registration statement for the shorter of 3 years from the effective date or such time as all shares covered under the registration statement have been sold. Under this agreement, if the registration statement is not declared effective within 150 days of the closing date, the Company shall be liable to pay each of the investors in cash an amount equal to 1.5% of their respective investment. Based on the aggregate investment in the Series B Preferred of \$6.0 million, the Company's exposure for penalties due to its failure to cause the registration statement to be declared effective on a timely basis would be \$90,000 per month, unless the investors waive such penalties. As of September 30, 2010, there have been no penalties accrued relating to the registration requirement because the Company believes it has or is likely to receive waivers of such requirement through the third quarter of 2010, and deems that any such potential future penalties are currently not probable.

14. STOCKHOLDERS' EQUITY:

The following table summarizes changes in components of stockholders' equity during the nine months ended September 30, 2010:

	Preferred Stock		Convertible Preferred Stock		Common Stock Issued	Paid – In	Accumulated	Total	
	Series A	Series A	Series B	Series B					Capital
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	(Deficit)
BALANCES, December 31, 2009	10,950	\$ 10,950	—	—	23,456,063	\$ 7,740,501	\$ 44,834,321	\$ (58,418,330)	\$ (5,832,558)

Preferred dividends	—	—	67	67	—	—	6,703	(59,777)	(53,007)
Issuance of convertible preferred stock, net of transaction costs	—	—	60,000	60,000	—	—	5,459,991	—	5,519,991
Stock-based compensation	—	—	—	—	—	—	965,077	—	965,077
Net income	—	—	—	—	—	—	—	1,320,160	1,320,160
BALANCES, September 30, 2010	10,950	\$ 10,950	60,067	\$ 60,067	23,456,063	\$ 7,740,501	\$ 51,266,092	\$ (57,157,947)	\$ 1,919,663

15. WARRANTS AND WARRANT DERIVATIVE LIABILITY

The following table summarizes warrants to purchase common stock activity for the period ended September 30, 2010:

	Amount	Range of Exercise Price
Warrants outstanding December 31, 2009	8,064,978	\$ 0.75 – 6.05
Issued	—	—
Cancelled/Expired	(572,417)	\$ 1.25 – 6.05
Warrants outstanding September 30, 2010	7,492,561	\$ 0.75 – 4.50

At September 30, 2010, stock purchase warrants will expire as follows:

	# of Warrants	Range of Exercise Price
2010	—	—
2011	2,301,419	\$ 0.75 – 4.50*
2012	818,000	\$ 2.00
2013	1,786,267	\$ 0.75 – 1.40*
2014	1,890,000	\$ 1.82 – 4.00
2015	696,875	\$ 1.25
Total	7,492,561	\$ 0.75 – 4.50

* Includes warrants that contain anti-dilution rights if the Company grants or issues securities for less than the exercise price.

Warrant Derivative Liability

At September 30, 2010, a total of 2,567,686 warrants are classified as a derivative liability pursuant to guidance codified in FASB ASC 815-40, Derivatives and Hedging, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock (previously EITF 07-5).

At September 30, 2010, the estimated fair value of these warrants, based on a Black-Scholes option pricing model was \$981 thousand, which is included in current liabilities in the accompanying condensed consolidated balance sheet. Based on the change in fair value of the warrant derivative liability, the Company recorded non-cash income of \$16 thousand and \$2.7 million for the three and nine months ended September 30, 2010, respectively. The warrant fair values at September 30, 2010 were determined using the Black-Scholes valuation model using the closing stock price at each date, volatility rate of 129-146%, risk free interest rates of 0.22-0.56%, and contractual lives equal to the remaining term of the warrants expiring as of each measurement date.

16. FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

Fair value is defined in ASC 820 as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are to be considered from the perspective of a market participant that holds the assets or owes the liability. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical or similar assets and liabilities.

13

Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial Instruments Measured at Fair Value on a Recurring Basis

ASC 820 requires disclosure of the level within the fair value hierarchy used by the Company to value financial assets and liabilities that are measured at fair value on a recurring basis. At September 30, 2010, the Company had outstanding warrants to purchase common shares of its stock that are classified as warrant derivative liabilities with a fair value of \$981 thousand. The warrants are valued using Level 3 inputs because there are significant unobservable inputs associated with them (See Note 15).

The table below sets forth a summary of changes in the fair value of the Company's warrant derivative liability for the period ended September 30, 2010:

	January 1, 2010	Gain on change in fair value included in earnings	September 30, 2010
Warrant Derivative Liability	\$ (3,666,336)	\$ 2,685,579	\$ (980,757)

Other Financial Instruments

The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities and deferred revenue approximate their respective fair values because of the short-term nature of these financial instruments.

The fair value of the Company's convertible debt is estimated to be \$375 thousand and \$950 thousand at September 30, 2010 and December 31, 2009, respectively, which is less than the carrying value of \$1.42 million at each of these dates. As described in Note 10, the current terms of the agreements relating to the convertible debt provides for the full settlement of the outstanding balance of the debt. Accordingly, the fair values noted above were estimated based on market value of 500,000 shares of the Company's common stock at September 30, 2010 and December 31, 2009.

The fair value of long-term investments were reported using the cost method as there are no quoted market prices available, and determining a reasonable estimate of fair value can not be completed without incurring excessive costs (See Note 9).

17. STOCK COMPENSATION

In September 2005, the Board of Directors of the Company approved the Amended and Restated 2005 Stock Option and Restricted Stock Plan (the "2005 SOP") and the Company's stockholders approved the 2005 SOP in November 2005. The 2005 SOP reserves 2,000,000 shares of common stock for grants of incentive stock options, nonqualified stock options, warrants and restricted stock awards to employees, non-employee directors and consultants performing services for the Company. The Company has stopped granting stock options under the 2005 SOP.

On March 11, 2009, the Board of Directors of the Company approved the 2009 Stock Option Plan (the "2009 SOP"), and the Company's stockholders approved the 2009 SOP on August 6, 2009. An aggregate of 3,000,000 shares of common stock have been reserved under the 2009 SOP for grants of incentive stock options, nonqualified stock

options, warrants and restricted stock awards to employees, non-employee directors and consultants performing services for the Company.

Options granted under the 2005 SOP and 2009 SOP have an exercise price equal to or greater than the fair market value of the underlying common stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options generally expire 10 years from the date of grant. Restricted stock awards granted under the 2005 SOP and 2009 SOP are subject to a vesting period determined at the date of grant.

In June 2010, the Company entered into a Release and Separation Agreement with the Company's former CEO and former members of the board of directors pursuant to which their respective stock option grants were modified (see Note 18). In connection with these modifications, the Company recorded incremental stock based compensation expense, based on the change in fair value of the modified options, of \$147 thousand during the quarter ended June 30, 2010. In addition, based on the continued vesting of certain of the stock options that were modified, the Company expects to record additional stock based compensation expense totaling approximately \$112 thousand ratably over a 12 month period through June 2011.

All options that the Company granted during the nine months ended September 30, 2010 were granted at the per share fair market value on the grant date. Vesting of options differs based on the terms of each option. The Company utilized the Black-Scholes option pricing model and the assumptions used for each period are as follows:

	Nine Months Ended September 30,	
	2010	2009
Weighted average risk free interest rate	1.59%	2.07%
Weighted average life (in years)	4.26 years	6.02 years
Volatility	118.69%	114.1%
Expected dividend yield	0%	0%
Weighted average grant-date fair value per share of options granted	\$ 0.61	\$.75

A summary of stock option activity for the nine months ended September 30, 2010 is presented below:

	Outstanding Options			
	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (1)
Balance at December 31, 2009(2)	5,821,000	\$ 1.36	6.15	\$ 4,401,385
Options Granted	1,005,000	\$ 1.23	9.46	
Exercised	—	—	—	
Forfeited	(1,801,928)	\$ 1.11		
Cancelled	—	—		
Balance at September 30, 2010	5,024,072	\$ 1.43	6.46	
Vested and exercisable as of September 30, 2010	2,670,978	\$ 1.65	5.79	—
Unvested as of September 30, 2010	2,353,094	\$ 1.18	7.23	\$ —

1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock prices of \$0.75 and \$1.90 of the Company's common stock at September 30, 2010 and December 31, 2009, respectively.

2) Includes 3,150,000 non-qualified options that were issued outside the 2005 and 2009 stock option plans.

The total grant date fair value of stock options granted during the three and nine months ended September 30, 2010 was \$103 and \$937 thousand, respectively. For the three and nine months ended September 30, 2010, stock based compensation was \$161 thousand and \$965 thousand, respectively, that included \$55 thousand for 75,000 shares of

restricted stock authorized but not issued to a consultant. For the three and nine months ended September 30, 2009, stock based compensation was \$325 thousand and \$897 thousand, respectively.

As of September 30, 2010, there were \$1.65 million of unrecognized compensation costs related to outstanding employee stock options. This amount is expected to be recognized over a weighted average period of 2.98 years. To the extent the forfeiture rate is different from what the Company anticipated; stock-based compensation related to these awards will be different from the Company's expectations.

18. RELATED PARTY TRANSACTIONS

A Plus International, Inc.

During the three and nine months ended September 30, 2010, the Company recognized cost of revenues of \$1.9 million and \$4.8 million respectively, relating to surgical products used in the Safety-Sponge® System manufactured by A Plus International or A Plus. At September 30, 2010, the Company's accounts payable included \$1.0 million owed to A Plus in connection with the purchase of surgical products used in the Safety-Sponge® System, \$9 thousand of which will be paid directly to A Plus by Cardinal Health pursuant to the new Supply and Distribution Agreement dated November 19, 2009. Wenchen Lin, a Director and significant beneficial owner of the Company is a founder and significant owner of A Plus. On June 24, 2010, A Plus converted \$1.0 million of accounts payable owed to A Plus into 10,000 shares of Series B Convertible Preferred Stock (see Note 13).

Francis Capital Management

On June 24, 2010, Catalysis Partners, LLC, invested \$1.0 million in the Series B Convertible Preferred Stock transaction (see Note 13). John P. Francis, a member of our Board of Directors, has voting and investment control over securities held by Francis Capital Management, LLC, which acts as the investment manager for Catalysis Partners, LLC.

Release and Separation Agreements

In connection with the Series B Convertible Preferred Stock financing (see Note 13), Steven H. Kane, the Company's former CEO, resigned as a Director, President and Chief Executive Officer, and Howard E. Chase, Loren McFarland, Eugene A Bauer, MD, and William M. Hitchcock also resigned as members of our Board of Directors (the "Board") and received certain severance benefits.

In connection with Mr. Kane's resignation, we entered into a Separation Agreement and Mutual General Release with Steven Kane (the "Kane Release"). Under the Kane Release, Mr. Kane will receive, subject to compliance with its terms, 12 months of salary and health payments, and waived his rights to any bonus payment, or payment for excise taxes. The Kane Release also provided for the payment to Mr. Kane, in cash, of an aggregate \$235 thousand as payment in full for all accrued Director Fees and salary, accrued vacation, and accrued severance benefits of \$349 thousand as of June 30, 2010 as provided in his employment agreement. The Kane Release contains other provisions, including provisions relating to stock options and other matters.

In connection with the resignation of Messrs. Chase, McFarland, Hitchcock and Dr. Bauer as members of our Board, effective as of June 24, 2010, we entered into a Separation Agreement and Mutual General Release with such individuals (the "Director Release"). The Director Release provided for the payment, in cash, of the following unpaid Director's fees not previously approved by the Compensation Committee: \$83.5 thousand to Mr. Chase, \$64.9 thousand to Mr. McFarland, \$10.0 thousand to Mr. Hitchcock and \$10.0 thousand to Dr. Bauer. The Director Release contains other provisions, including provisions relating to stock options and other matters.

19. MAJOR CUSTOMERS, SUPPLIERS, SEGMENT AND RELATED INFORMATION

Major Customers

During the three and nine months ended September 30, 2010, due to its exclusive distribution agreement with Cardinal Health, the Company had one customer that represented in excess of 97% and 98% of total revenues, respectively, compared with 89% and 80% for the same respective periods in 2009. No other single customer accounted for more than 10% of total revenues in either period.

Suppliers

The Company relies primarily on a third-party supplier, A Plus, to supply all the surgical sponges and towels used in its Safety-Sponge® System (see Note 18). The Company also relies on a number of third parties to manufacture certain other components of its Safety-Sponge® System. If A Plus or any of the Company's other third-party manufacturers cannot, or will not, manufacture its products in the required volumes, on a cost-effective basis, in a timely manner, or at all, the Company will have to secure additional manufacturing capacity. Any interruption or delay in manufacturing could have a material adverse effect on the Company's business and operating results.

Furthermore, the vast majority of products obtained from A Plus are manufactured in China. As such, the supply of product from A Plus is subject to various political, economic, and other risks and uncertainties inherent in importing products from this country, including among other risks, export/import duties, quotas and embargoes; domestic and international customs and tariffs; changing taxation policies; foreign exchange restrictions; and political conditions and governmental regulations.

Segment and Related Information

The Company presents its business as one reportable segment due to the similarity in nature of products marketed, financial performance measures, methods of distribution and customer markets. The Company's chief operating decision making officer reviews financial information on the Company's products on a consolidated basis. All revenues earned during the three and nine months ended September 30, 2010 relate to customers based in the United States.

The following table summarizes revenues by product line.

Three Months Ended September 30,	2010	2009
Revenues:		
Surgical sponges and towels	\$ 4,091,407	\$ 964,264
Scanners and related products	31,153	14,198
Total revenues	\$ 4,122,560	\$ 978,462
Nine Months Ended September 30,	2010	2009
Revenues:		
Surgical sponges and towels	\$ 10,166,752	\$ 2,586,079
Scanners and related products	86,145	355,987
Total revenues	\$ 10,252,897	\$ 2,942,066

20. COMMITMENTS AND CONTINGENCIES

Operating and Capital Leases

In November 2007, the Company entered into a 36 month lease agreement for approximately 4,000 square feet of office space in Temecula, CA, which expires December 31, 2010. Monthly lease payments for the remaining lease term of this lease are \$9,757. In November 2010, the Company moved its corporate headquarters to Irvine, CA, entering into a 36 month lease in September 2010 to lease approximately 3,300 square feet of office space. Monthly lease payments are \$5,610 a month during the first year and will increase 3% annually each year afterwards, effective each September. In December 2009, the Company entered into a 40 month sublease agreement for office space in Newtown, PA, which expires in April 2013, at a fixed monthly total lease payment for the entire term of the lease of

\$11,576. In connection with the Newtown, PA office sublease, the Company acquired certain office furniture valued at \$100 thousand from the building landlord for a nominal one-time payment. Accordingly, a portion of the total monthly lease payment for this facility has been allocated to the acquisition of this furniture and recorded as a capital lease at December 31, 2009.

In June 2010, the Company made the decision to close the Newtown, PA corporate office. Per FASB Accounting Standards Codification 420, Exit or Disposal Cost Obligations, the Company expensed the net present value of the remaining lease obligation along with an accrual for utilities through April 2013. At the time of management's decision in June 2010, the Company did not offset the lease accrual by any potential sublease income, as it was assumed at the time to be unlikely that a tenant would be found during the remaining sublease term due to local commercial real estate market conditions. Accordingly, in the quarter ended June 30, 2010, the Company recorded a charge of \$372 thousand for the remaining facility lease obligation. However as discussed in Note 21, the Company did subsequently find a prospective tenant, ("Tenant") to sublease the Newtown property, and entered into a sub-sublease agreement with Tenant on November 9, 2010 for the full lease period of the Company's original lease. As a result, the Company reduced its recorded lease obligation by \$220 thousand in the quarter ended September 2010, representing the net present value of expected future rent payments to be made by Tenant over the lease term. The sub-sublease arrangement is still subject to final approval by the Master Landlord and Sublease Landlord, which management expects shortly, however no assurances can be made that these required approvals will be received.

Contingent Tax Liability

In the process of preparing the Company's federal tax returns for prior years, the Company's management found there had been errors in reporting income to the recipients and the respective taxing authorities, related to stock grants made to certain employees and consultants. In addition, the Company determined that required tax withholding relating to these stock grants had not been made, reported or remitted, as required in 2006 and 2007. Due to the Company's failure to properly report this income and withhold/remit required amounts, the Company may be held liable for the amounts that should have been withheld, plus related penalties and interest. The Company has estimated its contingent liability based on the estimated required federal and state withholding amounts, the employee and employer portion of social security taxes as well as the possible penalties and interest associated with the error, and has submitted documentation to the Internal Revenue Service reporting the previously unreported income. Although the Company's liability may ultimately be reduced based either on the expiration of applicable statutes of limitations, or if it can prove that the taxes due on this income were paid on a timely basis by some or all of the recipients, the estimated liability including estimated interest and penalties, originally accrued by the Company was based on the assumption that it will be liable for the entire amounts due to the uncertainty with respect to whether or not the recipients made such payments.

On June 24, 2010, in connection with the Series B Convertible Preferred Stock Purchase Agreement, the Company entered into a Tax Escrow Agreement and transferred \$651 thousand into a tax escrow account. The Tax Escrow Agreement was entered into with the U.S. Bank National Association, a national banking association, acting as escrow agent. Under the Tax Escrow Agreement, the escrow agent is required to use the escrowed funds to pay specified tax claims to taxing authorities and/or to release escrowed funds to the extent the Company's tax reserve for the contingent tax liability has been reduced, subject to compliance with certain procedures.

During the nine months ended September 30, 2010, the Company reduced the tax escrow account by \$427 thousand based on the expiration of the statute of limitations during the quarter for certain amounts relating the tax year 2006. The Company anticipates the remaining \$224 thousand will be released from the escrow account in the third quarter of 2011. As of September 30, 2010, the remaining contingent tax liability, which is included in accrued liabilities, is \$224 thousand.

Legal Proceedings

On October 15, 2001, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. filed a lawsuit against the Company, Sunshine Wireless, LLC, and four other defendants affiliated with Winstar Communications, Inc. This lawsuit alleged that the Winstar defendants conspired to commit fraud and breached their fiduciary duty to the plaintiffs in connection with the acquisition of the plaintiff's radio production and distribution business. The complaint further alleged that the

Company and Sunshine joined the alleged conspiracy. On February 25, 2003, the case against the Company and Sunshine was dismissed. However, on October 19, 2004, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. exercised their right to appeal. On June 1, 2005, the United States Court of Appeals for the Second Circuit affirmed the February 25, 2003 judgment of the district court dismissing the claims against the Company.

On July 28, 2005, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. filed another lawsuit against the Company, Sunshine Wireless LLC and four other defendants affiliated with Winstar Communications to collect a federal default judgment of \$5.0 million entered against two entities, Winstar Radio Networks, LLC and Winstar Global Media, Inc., by attempting to enforce the judgment against the Company and others under the doctrine of de facto merger. The action was tried before the Los Angeles County Superior Court in 2008. On August 5, 2009, the Superior Court issued a statement of decision in the Company's favor, and on October 8, 2009, the Superior Court entered judgment in the Company's favor, and judged plaintiffs' responsible for \$2,709 of the Company's court costs. On November 6, 2009, the plaintiff filed a notice of appeal in the Superior Court of the State of California, County of Los Angeles Central District. The Company has engaged appellate counsel, believes the plaintiff's case is without merit and intends to continue to defend the case vigorously. As loss is not deemed to be probable in connection with this matter, no accruals have been made as of September 30, 2010.

21. SUBSEQUENT EVENTS

On October 22, 2010, the Company entered into an employment agreement and appointed David C. Dreyer as Chief Financial Officer and Vice President of the Company. Mr. Dreyer has over 20 years experience in financial management in public companies, including as Chief Financial Officer at AMN Healthcare Inc. (AHS) and Sicor Inc (now a part of Teva Pharmaceutical Industries Ltd [TEVA]).

As discussed in Note 10, Convertible Note Payable, in October 2010, the Company received a Notice of Levy (the "Levy") from the US Marshal's Office in Los Angeles ("Levying Officer") with an order requiring the Company to deliver all shares of Patient Safety Technologies common stock ("PST Stock") that the Company owes to Ault Glazer Capital Partners, LLC to the Levying Officer on behalf of a creditor who holds a judgment against Ault Glazer Partners, LLC and other parties. The Company is currently reviewing the Levy and intends to comply with its legal obligations in regard to the Levy (see Note 21).

On November 15, 2010 Zealous Asset Management LLC ("ZAM"), Managing General Partner for the hedge funds Zealous Partners and Ault Glazer Capital Partners filed a lawsuit in the Superior Court of California, County of Orange, Central Justice Center against the Company, Dr. Louis Glazer, one of our directors, and his spouse Melanie Glazer, as well as Steven Bodnar, a shareholder of the Company for breach of contract, breach of good faith, fraud and other claims (the "ZAM Suit"). The ZAM Suit alleges, among other things, that the Company's former management and the Glazers misrepresented the financial strength of the Company when re-negotiating terms of various loan agreements that the Company entered into with Zealous Partners and Ault Glazer Capital Partners in 2005 and 2006 and allegedly "forced" Ault Glazer Capital Partners to agree to such renegotiated terms. The ZAM Suit also contains allegations regarding dividends allegedly unpaid with respect to 2,600 shares of the Company's Series A Preferred Stock allegedly owned by an affiliate of ZAM. Management is still reviewing the ZAM Suit. The Company's preliminary analysis is that the ZAM Suit is without merit. The Company intends to vigorously defend the ZAM Suit and believes that this matter will not have any material impact to the financials statements of the Company.

As discussed in Note 20, Commitments and Contingencies, the Company made a decision in June 2010 to close its Newtown, PA corporate office. Per FASB Accounting Standards Codification 420, Exit or Disposal Cost Obligations, the Company expensed the net present value of the remaining lease obligation along with an accrual for utilities through April 2013, totaling \$372 thousand. The Company did not offset the lease accrual by any potential sublease, as it was assumed at the time to be unlikely that a tenant would be found during the remaining sublease term due to local commercial real estate market conditions. The Company did find a prospective tenant, ("Tenant") to sublease the Newtown property, and entered into a sub-sublease agreement with the Tenant on November 9, 2010 for the remaining lease period of the Company's original lease. As a result, the Company reduced its recorded lease obligation by \$220 thousand in the quarter ended September 30, 2010, representing the net present value of expected future rent payments to be made by Tenant over the lease term. The sub-sublease arrangement is still subject to final approval by the Master Landlord and Sublease Landlord, which is expected shortly, however no assurances can be

made that these required approvals will be received.

On November 15, 2010, the Company entered into an employment agreement, effective as of June 24, 2010, with Brian E. Stewart, President, Chief Executive Officer and Director of the Company, regarding his employment with the Company.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and the related notes thereto appearing elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes thereto and the description of our business appearing in our annual report on Form 10-K for the year ended December 31, 2009. This discussion contains forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements." Known and unknown risks, uncertainties and other factors could cause our actual results to differ materially from those projected in any forward-looking statements. In evaluating these statements, you should specifically consider various factors, including, but not limited to, those set forth under the caption "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2009.

Overview

We focus on the development, marketing and sales of products and services in the medical patient safety markets. Our proprietary Safety-Sponge® System is a patented system of bar-coded surgical sponges, SurgiCounter™ scanners, and software applications integrated to form a comprehensive counting and documentation system. This system is designed to eliminate the possibility of retained surgical sponges being unintentionally left inside of patients during surgical procedures by allowing faster and more accurate counting of surgical sponges. As of September 30, 2010, we reached a milestone of having had a cumulative total of over an estimated 36,625,000 of our sponges used in more than 1,450,000 procedures without a single undetected sponge left inside a surgical patient in all cases where our solution was utilized. We sell our Safety-Sponge® System to hospitals through our direct sales force, but rely on an exclusive distributor for the ongoing supply of our proprietary surgical sponge products to hospitals that have adopted our system. Our business model consists of selling our unique surgical sponge products, which are manufactured for us by an exclusive supplier, on a recurring basis to those hospitals that have adopted our Safety-Sponge® System. One of the ways in which we differentiate our products from other competing products is by working closely with hospital personnel through education and implementation services. We currently sell our Safety-Sponge® System only in the United States and we had revenues of \$4.1 million and \$10.3 million for the three and nine months ended September 30, 2010, which included \$2.5 million and \$5.9 million, respectively, shipped to Cardinal Health under the First Forward Order which does not necessarily represent sales of that product to end user hospitals (see "Factors Affecting Future Results —Cardinal Health Supply Agreement").

Sources of Revenues and Expenses

Revenues

Surgical Sponge Revenues. We generate revenues primarily from the sale of surgical sponges used in our Safety-Sponge® System to our exclusive distributor, who then sells directly and through sub-distributors to hospitals that have adopted our Safety-Sponge® System. We expect hospitals that adopt our Safety-Sponge® System to commit to its use and thus provide a recurring source of revenues from ongoing sales of surgical sponges and other products used in our system. We recognize revenues from the sale of surgical sponges upon shipment to our distributor because most of our surgical sponge sales are to our distributor, FOB shipping point. Note that because of the way our sales cycle works there is a gap between the time we begin incurring costs associated with our new customer arrangements and when we begin generating revenues from such arrangements.

Hardware, Software and Maintenance Agreement Revenues. We also generate revenues from the sale of related hardware and software to hospitals that have adopted our Safety-Sponge® System. The sale of our Safety-Sponge® System includes hardware (the SurgiCounter™ scanners and certain related hardware), our proprietary file management

software (Citadel™) and an initial one-year maintenance agreement (which may be renewed). All of these items are considered to be separate deliverables within a multiple-element arrangement and, accordingly, we allocate the total price of this arrangement among each respective deliverable, and recognize revenue as each element is delivered. For the hardware and software elements of our Safety-Sponge® System, we recognize revenues on delivery, which is the time of shipment (if terms are FOB shipping point) or upon receipt by the customer (if terms are FOB destination). Delivery with respect to our initial one-year maintenance agreements is considered to occur on a monthly basis over the term of the one-year period; we recognize revenues related to this element on a pro-rata basis during this period. Because of the change in our business model discussed below under “—Factors Affecting Future Results,” we do not expect these sales to represent a significant portion of our revenues going forward.

Prior to the third quarter of 2009, our business model included the sale of our SurgiCounter™ scanners and related software used in our Safety-Sponge® System to most hospitals that adopted our system. Beginning with the third quarter of 2009, we modified our business model and began to provide our SurgiCounter™ scanners and related software to all hospitals at no cost when they adopt our Safety-Sponge® System. Because we no longer engage primarily in direct SurgiCounter™ scanner sales, we generally anticipate only recognizing revenues associated with our SurgiCounter™ scanners in connection with reimbursement arrangements under our agreement with Cardinal Health. Therefore, we do not expect that our SurgiCounter™ scanners and related hardware will represent a sizable source of future revenues for us. Deferred scanner revenue associated with the reimbursement from Cardinal Health, will be recognized over the life of the specific hospital contract.

Cost of revenues

Our cost of revenues consists primarily of our direct product costs for surgical sponges and products from our exclusive third-party manufacturer. We also include a reserve expense for obsolete and slow moving inventory in cost of revenues. In addition, when we provide scanners to hospitals for their use (rather than sell), we include only the depreciation expense of the scanners in cost of revenues (not the full product cost). We estimate the useful life of the scanners to be three years. However, should we sell the scanners to hospitals, our cost of revenues include the full product cost when shipped.

Research and development expenses

Our research and development expenses consist of costs associated with the design, development, testing and enhancement of our products. We also include salaries and related employee benefits, research-related overhead expenses and fees paid to external service providers in our research and development expenses. There was a reclassification starting in 2010 of certain personnel-related expenses to sales and marketing expenses.

Sales and marketing expenses

Our sales and marketing expenses consist primarily of salaries and related employee benefits, sales commissions and support costs, professional service fees, travel, education, trade show and marketing costs.

General and administrative expenses

Our general and administrative expenses consist primarily of salaries and related employee benefits, professional service fees, expenses related to being a public entity, and depreciation and amortization expense.

Total other income (expense)

Our total other income (expense) primarily reflects changes in the fair value of warrants classified as derivative liabilities. Under applicable accounting rules (discussed below under “—Critical Accounting Policies—Warrant Derivative Liability”), we are required to make estimates of the fair value of our warrants each quarter, and to record the change in fair value each period in our statement of operations. As a result, changes in our stock price from period to period result in other income (when our stock price decreases) or other expense (when our stock price increases) on our income statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and

related disclosures in the financial statements. Critical accounting policies are those accounting policies that may be material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance. While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies used in the preparation of our financial statements require significant judgments and estimates. For additional information relating to these and other accounting policies, see Note 3 to our condensed consolidated interim financial statements.

Warrant Derivative Liability

Under applicable accounting guidance, an evaluation of outstanding warrants is made to determine whether warrants issued are required to be classified as either equity or a liability. Because certain warrants we have issued in connection with past financings contain certain provisions that may result in an adjustment to their exercise price, we classify them as derivative liabilities, and accordingly, we are then required to estimate the fair value of such warrants, at the end of each fiscal quarter. We use the Black-Scholes option pricing model to estimate such fair value, which requires the use of numerous assumptions, including, among others, expected life (turnover), volatility of the underlying equity security, a risk-free interest rate and expected dividends. The use of different values by management in connection with these assumptions in the Black Scholes option pricing model could produce substantially different results. Because we record changes in the fair value of warrants classified as derivative liabilities in total other income (expense), materially different results could have a material effect on our results of operations.

Goodwill

Our goodwill represents the excess of the purchase price over the estimated fair values of the net tangible and intangible assets of SurgiCount Medical, Inc., which we acquired in February 2005. We review goodwill for impairment at least annually in the fourth quarter, as well as whenever events or changes in circumstances indicate its carrying value may not be recoverable. We are required to perform a two-step impairment test on goodwill. In the first step, we will compare the fair value to its carrying value. If the fair value exceeds the carrying value, goodwill will not be considered impaired, and we are not required to perform further testing. If the carrying value exceeds the fair value, then we must perform the second step of the impairment test in order to determine the implied fair value of goodwill and record an impairment loss equal to the difference. Determining the implied fair value involves the use of significant estimates and assumptions. These estimates and assumptions include revenue growth rates and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, future economic and market conditions and determination of appropriate market comparables. We base our fair value estimates on assumptions we believe to be reasonable but that are unpredictable and inherently uncertain. Actual future results may differ from those estimates. To the extent additional events or changes in circumstances occur, we may conclude that a non-cash goodwill impairment charge against earnings is required, which could have an adverse effect on our financial condition and results of operations.

Stock-Based Compensation

We recognize compensation expense in an amount equal to the estimated grant date fair value of each option grant, or stock award over the estimated period of service and vesting. This estimation of the fair value of each stock-based grant or issuance on the date of grant involves numerous assumptions by management. Although we calculate the fair value under the Black Scholes option pricing model, which is a standard option pricing model, this model still requires the use of numerous assumptions, including, among others, the expected life (turnover), volatility of the underlying equity security, a risk free interest rate and expected dividends. The model and assumptions also attempt to account for changing employee behavior as the stock price changes and capture the observed pattern of increasing rates of exercise as the stock price increases. The use of different values by management in connection with these assumptions in the Black Scholes option pricing model could produce substantially different results.

Impairment of Long-Lived Assets

Our management reviews our long-lived assets with finite useful lives for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. We recognize an impairment loss when the sum of the future undiscounted net cash flows expected to be realized from the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured by the amount

by which the carrying amount of the asset exceeds its fair value. Considerable judgment is necessary to estimate the fair value of the assets and accordingly, actual results could vary significantly from such estimates. Our most significant estimates and judgments relating to the long-lived asset impairments include the timing and amount of projected future cash flows.

Accounting for Income Taxes

Deferred income taxes result primarily from temporary differences between financial and tax reporting. Deferred tax assets and liabilities are determined based on the difference between the financial statement basis and tax basis of assets and liabilities using enacted tax rates. Future tax benefits are subject to a valuation allowance when management is unable to conclude that our deferred tax assets will more-likely-than-not be realized from the results of operations. Our estimate for the valuation allowance for deferred tax assets requires management to make significant estimates and judgments about projected future operating results. If actual results differ from these projections, or if management's expectations of future results change, it may be necessary to adjust the valuation allowance.

Since January 1, 2007, we have measured and recorded uncertain tax positions in accordance with rules that took effect on such date that prescribe a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Accordingly, we now only recognize (or continue to recognize) tax positions meeting the more-likely-than-not recognition threshold (or that met such threshold on the effective date). Accounting for uncertainties in income tax positions involves significant judgments by management. If actual results differ from management's estimates, we may need to adjust the provision for income taxes.

Recent Accounting Pronouncements

For additional discussion regarding these, and other recent accounting pronouncements, see Note 3 to our condensed consolidated interim financial statements, appearing elsewhere in this quarterly report on Form 10-Q.

Internal Control Over Financial Reporting

In connection with our assessment of internal controls over financial reporting as of December 31, 2009, we identified the following material weaknesses in our internal control over financial reporting due to:

- Ineffective control environment due to the following identified weaknesses:
 - o Failure to retain individuals competent in the application of generally accepted accounting principles ("GAAP") to complex accounting transactions.
 - o Failure to establish sufficiently detailed accounting policies and procedures and to properly train accounting department staff.
 - Ineffective internal control policies and procedures relating to the period end close process including lack of controls relating to journal entries, post closing adjustments and management review of conclusions regarding accounting and financial reporting matters.
 - Ineffective internal control policies and procedures designed to provide reasonable assurance regarding the accuracy and integrity of spreadsheets used in the financial reporting system.

To remedy these material weaknesses, we are implementing policies and procedures to formalize our period end close process as well as to address the application of our accounting policies to ensure conformity with GAAP. We are also seeking to hire qualified personnel, or engage outside resources, as applicable, with appropriate knowledge/experience in the application of GAAP to complex accounting transactions and we are strengthening internal policies and procedures designed to ensure the accuracy and integrity of spreadsheets used in the financial reporting system. As discussed in Note 21, Subsequent Events, the Company hired a new Chief Financial Officer, Mr. Dreyer effective October 22, 2010. Mr. Dreyer is a Certified Public Accountant (CPA) with over 20 years experience in financial management of public companies. Management is fully committed to remediating the material weaknesses identified during last year's assessment of internal controls.

For information regarding our evaluation of the effectiveness of our disclosure controls and procedures as well as any changes in our internal control over financial reporting as of the end of the period covered by this report, see "Controls and Procedures" below.

Factors Affecting Future Results

Cardinal Health Supply Agreement. On November 19, 2009 we entered into a Supply and Distribution Agreement with Cardinal Health (which replaced our prior agreement with Cardinal Health) under which Cardinal Health is the exclusive distributor of current products used in our proprietary Safety-Sponge® System in the United States, Puerto Rico and Canada. In connection with the execution of this distribution agreement, Cardinal Health issued a \$10.0 million stocking purchase order ("First Forward Order"), paid us \$8.0 million in cash as a partial prepayment of the

Edgar Filing: Patient Safety Technologies, Inc - Form 10-Q

First Forward Order and agreed to pay \$2.0 million directly to A Plus International, Inc. ("A Plus"), our exclusive manufacturer, upon delivery of product to Cardinal Health. We did not ship any product pursuant to the First Forward Order in 2009, and accordingly, all \$10.0 million of revenue from the First Forward Order is expected to be recognized in 2010. As of September 30, 2010, we had recognized \$5.9 million in revenue from the First Forward Order, and Cardinal Health has made payments totaling \$2.0 million to A Plus. In addition, Cardinal Health had originally agreed to issue a \$5.0 million stocking purchase order ("Second Forward Order") before the end of the third quarter of 2010 if certain milestones were achieved, however both the Company and Cardinal Health have agreed not to pursue this Second Forward Order. We expect to have revenue of \$10.0 million in 2010 from the First Forward Order, and \$0 revenue from the First and Second Forward Orders in 2011.

Because of this arrangement, we expect that our revenues for 2010 will be significantly higher than the actual sales of our product by Cardinal Health to end-user hospital customers. However, the Company's revenue in 2011 and beyond could be materially lower than actual sales of our product made by Cardinal Health to end-user hospital customers. Under the terms of the Supply and Distribution Agreement with Cardinal Health, beginning in 2011 Cardinal Health may adjust its inventory to more normal levels gradually over a 12 month period. Should Cardinal Health reduce its orders to the Company in an effort to gradually reduce its inventory levels to more normal levels over a 12-month period, Company revenues could be materially negatively affected. The Company is in discussions with Cardinal Health to delay the reduction in 2011 and discuss a mutually acceptable process for Cardinal Health to use their Forward Order inventory in satisfying customer demand, so as to avoid having a significant negative impact if any, on the Company's future revenue in 2011 and beyond as a result of this arrangement, and believes that a mutual agreement will be reached between the Company and Cardinal Health, however no assurances can be made that such an agreement will be reached.

Effect of Stocking Sales and Backlog on Revenues. Our revenues reflect primarily the sale of surgical sponges to our exclusive distributor. Because we recognize revenues when we ship product, (1) the timing of orders by our distributor and the management of its inventory may affect the comparability of revenues between periods and (2) to the extent there is a backlog in receipt of products from our exclusive supplier of our surgical sponges, we may not always be able to recognize revenues in the same period in which a product order is received. In addition, our exclusive distributor may sell down its stocking inventory more than it anticipated, which could result in lower than anticipated Company revenue. Thus, certain changes in our revenues between periods are not necessarily reflective of actual hospital demand for our surgical sponge products during the period reported.

Reduction in Hardware Sales – Effect on Revenues and Cost of Revenues. Prior to the third quarter of 2009, our business model included the sale of our SurgiCounter™ scanners and related hardware and software used in our Safety-Sponge® System to most hospitals that adopted our system. Beginning with the third quarter of 2009, we modified our business model and began to offer to provide our SurgiCounter™ scanners and related hardware and software to hospitals at no cost when they adopt our Safety-Sponge® System. Because we no longer engage primarily in direct SurgiCounter™ scanner sales and generally anticipate only recognizing revenues associated with our SurgiCounter™ scanners in connection with reimbursement arrangements under our agreement with Cardinal Health, we do not expect our SurgiCounter™ scanners to continue to represent a sizable source of revenues for our company. For the three and nine months ended September 30, 2010, surgical sponge sales accounted for 99.2% and 99.1%, respectively, compared to 98.3% and 91.6%, respectively, for the same period in 2009. This change in our business model also affected our costs of revenues because rather than recognizing the full product cost for all SurgiCounter™ scanners at the time of shipment in our cost of revenues, we now recognize only the depreciation expense for those SurgiCounter™ scanners and related hardware that we have provided to certain hospitals for their use at no cost. This business model change led to a significant improvement in our gross margin in the year ended December 31, 2009 based on the shift in product mix resulting in a significantly higher percentage of surgical sponge sales, which are sold at a higher margin than our SurgiCounter™ scanners included in our cost of revenue. Going forward, we anticipate that the shift in product mix and anticipated increase in volume of surgical sponge sales will more than offset the effects of including depreciation expense for the scanners in cost of revenue without generating the corresponding revenue from the sale of the scanner.

Results of Operations

Three Months Ended September 30, 2010 Compared to Three Months Ended September 30, 2009

Revenues

We had revenues of \$4.1 million, which included \$2.5 million shipped to Cardinal Health under the First Forward Order (see “Factors Affecting Future Results —Cardinal Health Supply Agreement” above) for the three months ended September 30, 2010. Estimated hospital consumption revenue, which is defined as total revenue less the First Forward Order was \$1.6 million for the three months ended September 30, 2010, an increase of 69.6% compared to \$978 thousand for the same period in 2009. In the three months ended September 30, 2010, surgical sponge sales accounted for 99.2% of revenue, and sales of hardware accounted for 0.8%, compared to 98.3% and 1.7% for the same period in 2009, respectively. The primary reason for the increase in revenues was an increase in the number of hospitals implementing the Safety-Sponge® System and the shipment of Forward Order inventory to Cardinal Health (see “Factors Affecting Future Results —Cardinal Health Supply Agreement”). New hospital implementations were driven by a number of factors, including increasing industry awareness of our product offering and growing evidence of its clinical effectiveness.

Cost of revenues

Cost of revenues increased by \$1.4 million or 261%, to \$1.95 million for the three months ended September 30, 2010 from \$540 thousand for the same period in 2009. The increase was primary due to an increase in sales of our products used in our Safety-Sponge® System, reflecting an increase in the number of hospitals that have adopted and implemented our system, along with \$ 940 thousand, associated with the shipment of product to Cardinal Health (see “Factors Affecting Future Results —Cardinal Health Supply Agreement”). The increase in costs associated with the increase in product sales more than offset the decrease in costs that resulted from the change in our business model with respect to the provision of our SurgiCounter™ scanners, which resulted in approximately \$1.0 million of cost now being depreciated and recognized over the life of the hardware.

Gross profit

We had gross profit of \$2.2 million for the three months ended September 30, 2010, an increase of \$1.7 million, or 395%, compared to \$438 thousand in the same period in 2009. The primary reason for the increase in gross profit during the three months ended September 30, 2010, was the higher revenue growth achieved with both Forward Order inventory sales to Cardinal Health and hospital customers. We had gross margin of 52.7% for the three months ended September 30, 2010, compared to 44.8% for the same period in 2009. This improvement in gross margin was primarily attributable to a product mix shift away from lower margin scanning hardware and increased pricing on the sale of our sponge products to new customers.

Operating expenses

We had total operating expenses of \$1.2 million for the three months ended September 30, 2010, a decrease of \$689 thousand, or 35.6%, compared to \$1.9 million for the same period in 2009. This reduction in operating expenses is primarily due to the impact of a comprehensive restructuring program implemented by new management during the third quarter of 2010 focused on a number of initiatives, including reducing operating expenses and achieving positive operating income and operating cash flow. Restructuring activities included the elimination of certain job positions, lowering executive and employee cash compensation levels, refining and enforcing expense and travel policies and initiating spend measurement systems and accountability across various functional areas. As a result of a number of factors, primarily the continued growth of the Company’s revenues from both delivery of the Cardinal Health’s stocking inventory (as discussed in Note 12) and hospital consumption, and the impact on operating expenses from the restructuring initiative, the Company reported positive operating income of \$925 thousand during the most recent quarter ended September 30, 2010, the first period of positive reported operating income in the history of the Company’s ownership of SurgiCount since 2005.

Research and development expenses

We had research and development expenses of \$35 thousand for the three months ended September 30, 2010, a decrease of \$34 thousand, or 49.1%, compared to \$69 thousand in the same period in 2009. The primary reason for the decrease was management prioritizing the level of spending on research and development activities to those that lend themselves to product enhancements and extensions to the Company’s current core product focus.

Sales and marketing expenses

We had sales and marketing expenses of \$519 thousand for the three months ended September 30, 2010, a decrease of \$91 thousand, or 15%, compared to \$610 thousand in the same period in 2009. The primary reason for the decrease in sales and marketing expenses were expense reductions including travel and entertainment.

General and administrative expenses

We had general and administrative expenses of \$693 thousand for the three months ended September 30, 2010, a decrease of \$563 thousand, or 45%, compared to \$1.3 million in the same period in 2009. The decrease in general and administrative expense was primarily due to the elimination of certain positions, the reduction of cash compensation, refining and enforcing expense and travel policies and the reduction of consulting expenses. Additionally, during the three months ended 2009 general and administrative expenses also included a \$214 thousand charge for amortization of debt discount, which is \$0 in the third quarter of this year as the debt discount was fully amortized at the end of 2009.

Total other income (expense)

We had total other income of \$19 thousand for the three months ended September 30, 2010, compared to total other expense of \$1.9 million in the same period in 2009. The primary reason for the change was a decrease in the fair value of our warrant derivative liability, which resulted in income of \$16 thousand in the three months ended September 30, 2010, compared to a loss of \$1.8 million in the same period last year, when the fair value of our warrant liability went up. This liability, and the related expense, increases and decreases as a direct result of fluctuations in the price of our common stock, which trades on the over the counter market. Excluding the effects of the changes in the fair value of our warrant derivative liability, we only had a slight amount interest income this quarter, whereas it was interest expense of \$304 thousand in the same period last year.

Provision for income taxes

We had a \$33 thousand tax benefit for the three months ended September 30, 2010, compared to a \$32 thousand tax benefit for the same period in 2009. Despite the fact that the company generated positive net income before taxes of \$944 thousand during the current quarter, the tax benefit relates to the amortization of the Company's patent portfolio. An in-depth tax provision calculation will be prepared at yearend, based on the Company's final taxable income amount reported.

Net income

Due to a number of factors, including the increases in this quarter's revenue and gross profit, along with the significant reductions in operating expenses, we had net income of \$962 thousand for the three months ended September 30, 2010 compared to a net loss of \$3.4 million for the same period in 2009.

Nine Months Ended September 30, 2010 Compared to Nine Months Ended September 30, 2009

Revenues

We had revenues of \$10.3 million, which included \$5.9 million shipped to Cardinal Health under the First Forward Order (see "Factors Affecting Future Results —Cardinal Health Supply Agreement") for the nine months ended September 30, 2010. Therefore, estimated hospital consumption revenue (defined as total revenue less amounts shipped to Cardinal Health under the First Forward Order) was \$4.4 million for the nine months ended September 30, 2010, an increase of 49% compared to \$2.9 million for the same period in 2009. In the nine months ended September 30, 2010, surgical sponge sales accounted for 99.2% of revenues, and sales of hardware accounted for 0.8%, compared to 98.3% and 1.7% for the same period in 2009, respectively. The primary reason for the increase in revenues was an increase in the number of hospitals implementing the Safety-Sponge® System and the shipment of Forward Order inventory to Cardinal Health. New hospital implementations were driven by a number of factors, including increasing industry awareness of our product offering and growing evidence of its clinical effectiveness.

Cost of revenues

Cost of revenues increased by \$3.1 million or 182.8%, to \$4.8 million for the nine months ended September 30, 2010 from \$1.7 million for the same period in 2009. This increase was primarily due to an increase in sales of our products used in our Safety-Sponge® System from mostly new customer business as well as growth in usage by existing customers, reflecting an increase in the number of hospitals that have adopted and implemented our system. The cost of sales increase also reflects \$2.8 million in costs associated with the shipment of \$5.9 million of Forward Inventory product to Cardinal Health (see “Factors Affecting Future Results —Cardinal Health Supply Agreement”). The increase in costs associated with the increase in sales of products more than offset the decrease in costs that resulted from the change in our business model with respect to the provision of our SurgiCounter™ scanners, which resulted in approximately \$1.0 million of cost now being depreciated and recognized over the life of the hardware.

Gross profit

We had gross profit of \$5.4 million for the nine months ended September 30, 2010, an increase of \$4.2 million, or 339%, compared to \$1.2 million during the same period in 2009. The primary reason for the increase in gross profit during the nine months ended September 30, 2010, was higher revenue growth achieved, with both hospital customers and Forward Order inventory sales to Cardinal Health. We had gross margin of 52.9% for the nine months ended September 30, 2010, compared to 42.0% for the same period in 2009. This improvement in gross margin was primarily attributable to a product mix shift away from lower margin scanning hardware and increased pricing on the sale of our sponge products to new customers.

Operating expenses

We had total operating expenses of \$7.4 million for the nine months ended September 30, 2010, an increase of \$115 thousand, or 1.6%, compared to \$7.2 million for the same period in 2009. The increase in operating expense was generally insignificant as the Company held its spending on operating expenses generally in line with last years spending levels, even though hospital consumption revenue which is defined as total revenue less the First Forward Order sales to Cardinal grew by \$1.5 million or 49% compared to last year. Management initiated a comprehensive restructuring program during the third quarter of 2010 focused on a number of initiatives, including reducing operating expenses and achieving positive operating income and operating cash flow. Restructuring activities included the elimination of certain job positions, lowering executive and employee cash compensation levels, refining and enforcing expense and travel policies and initiating spend measurement systems and accountability across various functional areas.

Research and development expenses

We had research and development expenses of \$167 thousand for the nine months ended September 30, 2010, a decrease of \$101 thousand, or 37.8%, compared to \$268 thousand in the same period in 2009. The primary reason for this decrease was the reprioritization of spending to research and development activities to those that lend themselves to product enhancements and extensions to the Company's existing core product focus during the third quarter of 2010 and a reclassification of certain personnel-related expenses to sales and marketing expenses.

Sales and marketing expenses

We had sales and marketing expenses of \$2.3 million for the nine months ended September 30, 2010, an increase of \$529 thousand, or 29.2%, compared to \$1.8 million in the same period in 2009. The primary reason for the increase in sales and marketing expenses was an increase in personnel, travel, entertainment and trade show related expenses during the first and second quarters of 2010, in addition to increased clinical implementation related expenses, which supported new customer growth with expanded adoption of our Safety-Sponge® System.

General and administrative expenses

We had general and administrative expenses of \$4.8 million for the nine months ended September 30, 2010, a decrease of \$313 thousand, or 6.1%, compared to \$5.2 million for the same period in 2009. This decrease was due to lower expenses in stock compensation, depreciation and other G&A expenses as a result of management's recent efforts to lower spending during the third quarter 2010, offset by higher expenses for severance, rent and legal expenses due to severance accrued for former employees, rent costs from closing our Newtown office location, and legal expenses associated with the recent recapitalization, all of which occurred in June 2010 as a part of the Company's restructuring. While the general and administrative expenses for the nine months ended September for both this year and 2009 appear generally comparable, the trends of the third quarter 2010 suggest the Company is

running at an annualized spending level that is significantly lower than the prior year.

Total other income (expense)

We had total other income of \$3.1 million for the nine months ended September 30, 2010, compared to total other expense of \$4.9 million in the same period in 2009. The primary reason for the change was a significant decrease in the fair value of our warrant derivative liability, which resulted in income of \$2.7 million in the nine months ended September 30, 2010, compared to a loss of \$ 4.3 million during the same period in 2009. This liability, and the related expense, increases and decreases as a direct result of fluctuations in the price of our common stock, which trades on the over the counter market. Excluding the effects of the changes in the fair value of our warrant derivative liability, our other expense decreased, primarily due to a significant decrease in our interest expense, which decreased due to the settlement of our outstanding indebtedness in the fourth quarter 2009.

Provision for income taxes

We had a \$140 thousand tax benefit for the nine months ended September 30, 2010, compared to a \$96 thousand tax benefit for the same period in 2009. Despite the fact that the company generated positive net income before taxes of \$1.2 million for the nine months ended September 30, 2010, the tax benefit assumes amortization of the Company's patent portfolio. An in-depth tax provision calculation will be prepared at yearend, based on the Company's final taxable income amount reported.

Net income (loss)

As a result of the foregoing results discussed above, we had net income of \$1.3 million for the nine months ended September 30, 2010 compared to a net loss of \$10.9 million for the same period in 2009.

Financial Condition, Liquidity and Capital Resources

We had cash and cash equivalents totaling \$3.0 million at September 30, 2010 compared to \$3.4 million at December 31, 2009. The cash balance as of September 30, 2010 included restricted cash of \$224 thousand compared to \$0 restricted cash at December 31, 2009. The restricted cash balance is due to the establishment of the Tax Escrow Account (see Note 20, Commitments and Contingencies to our condensed consolidated interim financial statements). As of September 30, 2010 we had a working capital deficit of \$3.7 million, of which \$4.4 million is associated with deferred revenue related to the partial prepayment from Cardinal Health and \$981 thousand relates to the warrant derivative liability (see explanations at Notes 12 and 15 to our condensed consolidated interim financial statements).

Our principal sources of cash have historically included the issuance of equity and debt securities. Starting in the most recent quarter ended September 30, 2010, newly appointed management implemented a comprehensive restructuring effort focused on a number of initiatives, including reducing operating expenses and achieving positive operating income and operating cash flow (see Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS). During the most recent quarter ended September 30, 2010, the Company reported positive operating income of \$925 thousand, which is the first period of reported positive operating income since the Company's acquisition of SurgiCount in 2005. The operating income of \$925 thousand during the quarter ended September 30, 2010 included \$1.3 million of gross profit attributable to sales to Cardinal Health, our exclusive distributor, under our agreement with them that includes provisions for their purchase of inventory stocking orders throughout 2010. Also during the most recent quarter ended September 30, 2010 the Company had negative cash flow from operations of \$2.0 million, however, excluding a one-time payment of \$2.4 million to the provider of our sponge products, A Plus International, Inc., for significantly past due amounts owed for previously delivered inventory, adjusted cash flow from operations would have been a positive \$315 thousand. The improvement in operating income and cash flow from operations in the third quarter of 2010 compared to previous periods was the result of a number of items, including the restructuring initiative recently implemented by newly

appointed management and the continued growth in the Company's revenue, which included inventory sales to Cardinal Health attributable to stocking orders.

Our sales cycle typically requires that we incur expenses in advance of the time we generate revenues from our new customer arrangements. Such expenses include sales and marketing costs, funding product trials, purchasing scanning hardware and funding new hospital implementations and education. Thus, as our business grows and we expand our customer base, our cash needs tend to increase prior to the time we generate cash from such new customer arrangements. We entered into a financing transaction in June 2010 that resulted in the receipt of \$4.5 million of cash, net of transaction costs and a \$1.0 million reduction in accounts payable (by A Plus International, Inc., our exclusive supplier). Although management believes its existing cash resources, as augmented by the financing last June, combined with improved projected cash flow from operations, will be sufficient to fund the Company's working capital requirements at least through the first quarter of 2011. In order to continue to operate as a going concern and make investments in product development and sales and marketing to facilitate future sales growth, it will be necessary to raise additional funds during 2011. Management believes that it will be able to obtain such financing at reasonable terms and that, if necessary, additional cost-cutting measures can be implemented to extend our ability to operate our core business even if financing is not timely available. However, no assurances can be made that we will be successful in obtaining a sufficient amount of financing on acceptable terms (or any financing), or that we will be able to continue to fund our operations or achieve consistent profitable results and positive cash flow. In addition, no assurance can be made that additional cost cutting measures, in addition to what management has already implemented, will be successful in extending the Company's ability to operate effectively without procuring additional financing.

Finally, although the Company believes it will be able to reach an arrangement with Cardinal Health to delay or avoid reductions of its stocking inventory levels beginning in 2011, which could materially impact the Company's future revenues, no assurance can be made that an agreement will be reached, or reached in a timely manner.

Operating activities

We used \$4.3 million of net cash from operating activities in the nine months ended September 30, 2010. Non-cash adjustments to reconcile net income to net cash used in operating activities plus changes in operating assets and liabilities used \$5.6 million of cash for the nine months ended September 30, 2010. These significant non-cash adjustments primarily reflect adjustments to reflect the change in fair value of our warrant derivative liability, deferred revenue adjustments relating to shipments to Cardinal Health, and increased inventory balances.

Investing activities

We used \$628 thousand of net cash in investing activities during the nine months ended September 30, 2010, primarily for the purchase of scanners and related hardware used in our Safety Sponge® System.

Financing activities

We generated \$4.2 million of net cash from financing activities in the nine months ended September 30, 2010, primarily from the net proceeds of the \$6.0 million issuance of Series B Convertible Preferred Stock in June 2010 (\$5.0 million in cash proceeds and \$1.0 million in reductions of our accounts payable), offset with the write-off of capital lease obligations following the closure of the Newtown, PA office, and the payment of preferred stock dividends. See Note 20 to our condensed consolidated interim financial statements for further discussion.

On June 24, 2010, in connection with the Convertible Preferred Stock Purchase Agreement, the Company entered into a Tax Escrow Agreement and transferred \$651 thousand into a tax escrow account. Under the Tax Escrow Agreement, the escrow agent, U.S. Bank National Association, is required to use the escrowed funds to pay specified tax claims to taxing authorities and/or to release escrowed funds to the extent the Company's tax reserve for the contingent tax liability has been reduced, subject to compliance with certain procedures. During the quarter ended September 2010, \$428 thousand of the restricted cash balance was released due to the statute of limitations passing on certain of the tax claims that were initially held in escrow, leaving a balance of \$224 thousand as of September 30, 2010.

Description of Indebtedness

At September 30, 2010, we had aggregate indebtedness of \$1.4 million pertaining to the Ault Glazer Capital Partners LLC note as described below.

Ault Glazer Capital Partners, LLC

On September 5, 2008, we entered into an Amendment and Early Conversion of Secured Convertible Promissory Note ("Amendment"), with Ault Glazer Capital Partners, LLC, or Ault Glazer, to modify the terms of our outstanding \$2.5 million convertible secured promissory note (issued to Ault Glazer effective as of June 1, 2007). This convertible secured note was to have matured on December 31, 2010, bore interest at a rate of 7% per annum, was convertible into shares of our common stock at \$2.50 per share in certain circumstances, and was secured by all of our assets. Under the Amendment, we agreed to pay Ault Glazer \$450 thousand in cash and, contingent upon satisfaction of certain conditions by Ault Glazer, to convert the remaining balance of the convertible secured note into 1,300,000 shares of our common stock. Notably, one condition was that Ault Glazer transfers certain leases from our name into its name.

On September 12, 2008, we entered into an Agreement for the Advancement of Common Stock Prior to Close of the Amendment and Early Conversion of Secured Convertible Promissory Note ("Advancement"), whereby we agreed to issue shares of our common stock to Ault Glazer in advance of its satisfaction of the conditions for the conversion of the convertible secured note that were set out in the Amendment. As of the date of this quarterly report on Form 10-Q, we have paid Ault Glazer \$450 thousand in cash and issued Ault Glazer aggregate 800,000 shares of our common stock in settlement of the promissory note in advance of conversion of the note. Ault Glazer has not yet satisfied the conditions set out in the Amendment, and the issuance of the remaining shares of our common stock to Ault Glazer remains contingent upon its satisfaction of such conditions. In light of the Amendment and issuance of shares pursuant to the Advancement and Ault Glazer's failure to satisfy the conditions, we are no longer incurring interest expense on this convertible secured promissory note. As of September 30, 2010, the outstanding principal balance on this note was \$1.4 million. For further information relating to this note, see Note 10 to our condensed consolidated interim financial statements.

As discussed in Note 21 Subsequent Events, the Company received a Notice of Levy (the “Levy”) from the US Marshal’s Office in Los Angeles (“Levying Officer”) with an order requiring the Company to deliver all shares of Patient Safety Technologies stock (“PST Stock”) that the Company owes to Ault Glazer Capital Partners, LLC to the Levying Officer as settlement of a creditor judgment against Ault Glazer Partners, LLC and other parties. The Company is currently reviewing the Levy and intends to comply with the associated legal obligations.

Investment Portfolio

At September 30, 2010, we had an investment in preferred stock of Alacra, Inc., with a carrying value of \$667 thousand, which represented 5.5% of our total assets at September 30, 2010. In December 2007, we received proceeds of \$333 thousand from the redemption of one-third of our initial \$1.0 million investment. In accordance with the terms of our investment, we have exercised our right to redeem our remaining preferred stock to Alacra, however to date Alacra has not complied with our redemption rights. We intend to exercise all of our rights and expect to receive the full carrying value due to us from this investment. As there is no readily determinable fair value of the Alacra preferred stock, we account for this investment under the cost method. For additional information relating to this investment, see Note 9 to our condensed consolidated interim financial statements.

Related Party Transactions

We have an exclusive supply agreement for surgical sponges used in our Safety-Sponge® System with A Plus International Inc. Wenchen Lin, a member of our Board of Directors, is a founder and significant beneficial owner of A Plus. In addition, Mr. Lin has participated in prior equity financings of our company. During the three and nine months ended September 30, 2010, our cost of revenue included \$1.9 million and \$4.6 million in connection with this supply arrangement, and our accounts payable included \$1.0 million at September 30, 2010, payable to A Plus under this supply agreement, which includes \$9 thousand that will be paid directly to A Plus by Cardinal Health (see “—Factors Affecting Future Results—Cardinal Health Supply Agreement” above). On June 24, 2010, A Plus converted \$1,000,000 of accounts payable owed to A Plus into 10,000 shares of Series B Convertible Preferred Stock (see Note 13).

On June 24, 2010, John P. Francis, a member of our Board of Directors, who has voting and investment control over securities held by Francis Capital Management, LLC, which acts as the investment manager for Catalysis Partners, LLC, invested \$1.0 million in the Series B Convertible Preferred Stock transaction.

In the past, we used the services of an aircraft owning partnership principally owned by Steven H. Kane, our former Chief Executive Officer for air travel. During the three and nine months ended September 30, 2010, there were \$0 and \$19 thousand, respectively, in expenses related to the use such air travel services. During the three and nine months ended September 30, 2009, there were no expenses related to the use such air travel services.

For additional information relating to these and other related party transactions, see Note 18 to our condensed consolidated interim financial statements.

Off-Balance Sheet Arrangements

As of September 30, 2010, we had no off-balance sheet arrangements.

Commitments and Contingencies

As of September 30, 2010, other than our office leases and employment agreements with key executive officers and the litigation described in Item 1 of Part II of this Form 10Q, we had no material commitments or contingencies other than the liabilities reflected in our condensed consolidated interim financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Limitations on the Effectiveness of Controls

We seek to improve and strengthen our control processes to ensure that all of our controls and procedures are adequate and effective. We believe that a control system, no matter how well designed and operated, can only provide reasonable, not absolute, assurance that the objectives of the control system are met. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. No evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company will be detected.

As discussed in Note 21, Subsequent Events, on October 22, 2010, the Company entered into an employment agreement and appointed David C. Dreyer as Chief Financial Officer and Vice President of the Company. Mr. Dreyer has over 20 years experience in financial management of public companies, including as Chief Financial Officer at AMN Healthcare Inc. (AHS) and Sicor Inc (acquired by Teva Pharmaceutical Industries Ltd [TEVA]).

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act. Based upon that evaluation, our chief executive officer and chief financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective because the material weaknesses in our internal control over financial reporting described below identified in our assessment of internal control over financial reporting as of December 31, 2009 had not been fully remediated.

Material Weaknesses in Internal Control Over Financial Reporting

In connection with our assessment of internal controls over financial reporting as of December 31, 2009, we identified the following material weaknesses in our internal control over financial reporting due to:

- Ineffective control environment due to the following identified weaknesses:
 - o Failure to retain individuals competent in the application of generally accepted accounting principles (“GAAP”) to complex accounting transactions.
 - o Failure to establish sufficiently detailed accounting policies and procedures and to properly train accounting department staff.
 - Ineffective internal control policies and procedures relating to the period end close process including lack of controls relating to journal entries, post closing adjustments and management review of conclusions regarding accounting and financial reporting matters.
 - Ineffective internal control policies and procedures designed to provide reasonable assurance regarding the accuracy and integrity of spreadsheets used in the financial reporting system.

To remedy these material weaknesses, we are implementing policies and procedures to formalize our period end close process as well as to address the application of our accounting policies to ensure conformity with GAAP. We are also seeking to hire qualified personnel, or engage outside resources, as applicable, with appropriate knowledge/experience in the application of GAAP to complex accounting transactions and we are strengthening internal policies and procedures designed to ensure the accuracy and integrity of spreadsheets used in the financial reporting system. As discussed in Note 21 “Subsequent Events”, the Company recently hired a new Chief Financial Officer, is fully committed to remedying the material weaknesses identified during last year’s assessment of internal controls.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended) during the most recent fiscal quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On October 15, 2001, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. filed a lawsuit against us, Sunshine Wireless, LLC, and four other defendants affiliated with Winstar Communications. This lawsuit alleged that the Winstar defendants conspired to commit fraud and breached their fiduciary duty to the plaintiffs in connection with the acquisition of the plaintiff's radio production and distribution business. The complaint further alleged that the Company and Sunshine joined the alleged conspiracy. On February 25, 2003, the case against the Company and Sunshine was dismissed. However, on October 19, 2004, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. exercised their right to appeal. On June 1, 2005, the United States Court of Appeals for the Second Circuit affirmed the February 25, 2003 judgment of the district court dismissing the claims against the Company.

On July 28, 2005, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. filed another lawsuit against the Company, Sunshine and four other defendants affiliated with Winstar. That lawsuit attempted to collect a federal default judgment of \$5.0 million entered against two entities, Winstar Radio Networks, LLC and Winstar Global Media, Inc., by attempting to enforce the judgment against the Company and others under the doctrine of de facto merger. The action was tried before a Los Angeles County Superior Court judge, without a jury, in 2008. On August 5, 2009, the Superior Court issued a statement of decision in the Company's favor, and on October 8, 2009, the Superior Court entered judgment in the Company's favor, and judged plaintiffs' responsible for \$2,709 of the Company's court costs. On November 6, 2009, the plaintiffs filed a notice of appeal in the Superior Court of the State of California, County of Los Angeles Central District. The Company has engaged appellate counsel, believes the plaintiff's case to be without merit and intends to continue to defend the case vigorously.

ITEM 1A. RISK FACTORS

Refer to the risk factors discussed in the Company's 2009 Annual Report on Form 10K, filed on March 31, 2010.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4. (REMOVED AND RESERVED)

ITEM 5. OTHER INFORMATION

Not applicable

ITEM 6. EXHIBITS

Exhibit Number	Description
10.1	Employment Agreement dated August 9, 2010 between Patient Safety Technologies, Inc. and Jack A. Hamilton (incorporated by reference to our current report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on August 9, 2010)
31.1*	Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)*
31.2*	Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)*
32.1*	Certification of Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code*

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PATIENT SAFETY TECHNOLOGIES, INC.

Date: November 19, 2010

By: /s/ Brian E. Stewart
Brian E. Stewart, President and Chief
Executive Officer

Date: November 19, 2010

By:/s/ David C. Dreyer
David C. Dreyer, Vice President,
Chief Financial Officer, and Treasurer